The  	The  	 DT	O
Antihypertensive  	Antihypertensive  	 NNP	B-NP
and  	and  	 CC	O
Lipid  	Lipid  	 NNP	B-NP
Lowering  	Lowering  	 NNP	I-NP
Treatment  	Treatment  	 NNP	I-NP
to  	to  	 TO	O
Prevent  	Prevent  	 VB	O
Heart  	Heart  	 NNP	B-NP
Attack  	Attack  	 NNP	I-NP
Trial  	Trial  	 NNP	I-NP
( 	( 	 -LRB-	O
ALLHAT 	ALLHAT 	 NNP	O
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
a  	a  	 DT	O
randomized 	randomized 	 NN	O
,  	,  	 ,	O
two-component  	two-component  	 JJ	B-NP
clinical  	clinical  	 JJ	I-NP
trial  	trial  	 NN	I-NP
sponsored  	sponsored  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
National  	National  	 NNP	B-NP
Heart 	Heart 	 NNP	I-NP
,  	,  	 ,	O
Lung 	Lung 	 NNP	O
,  	,  	 ,	O
and  	and  	 CC	O
Blood  	Blood  	 NNP	O
Institute  	Institute  	 NNP	O
( 	( 	 -LRB-	O
NHLBI 	NHLBI 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
double-blind 	double-blind 	 JJ	B-NP
,  	,  	 ,	O
active-controlled  	active-controlled  	 JJ	O
hypertension  	hypertension  	 NN	O
component  	component  	 NN	O
is  	is  	 VBZ	O
designed  	designed  	 VBN	O
to  	to  	 TO	O
compare  	compare  	 VB	O
the  	the  	 DT	O
rate  	rate  	 NN	O
of  	of  	 IN	O
fatal  	fatal  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
heart  	heart  	 NN	I-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
CHD 	CHD 	 NNP	B-NP
)  	)  	 -RRB-	O
or  	or  	 CC	O
nonfatal  	nonfatal  	 FW	B-NP
myocardial  	myocardial  	 FW	I-NP
infarction  	infarction  	 FW	I-NP
( 	( 	 -LRB-	O
MI 	MI 	 NNP	O
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
the  	the  	 DT	O
primary  	primary  	 JJ	B-NP
endpoint 	endpoint 	 NN	I-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
high-risk  	high-risk  	 JJ	B-NP
hypertensive  	hypertensive  	 JJ	I-NP
participants 	participants 	 NNS	I-NP
,  	,  	 ,	O
aged  	aged  	 VBN	O
55  	55  	 CD	O
years  	years  	 NNS	O
or  	or  	 CC	O
older 	older 	 JJR	O
,  	,  	 ,	O
between  	between  	 IN	O
those  	those  	 DT	O
randomized  	randomized  	 NN	O
to  	to  	 TO	O
treatment  	treatment  	 VB	O
initiated  	initiated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
diuretic  	diuretic  	 NN	B-NP
( 	( 	 -LRB-	O
chlorthalidone 	chlorthalidone 	 LS	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
treatment  	treatment  	 NN	O
initiated  	initiated  	 VBN	O
with  	with  	 IN	O
each  	each  	 DT	O
of  	of  	 IN	O
three  	three  	 CD	O
alternative  	alternative  	 NN	B-NP
antihypertensive  	antihypertensive  	 NN	I-NP
drugs 	drugs 	 NNS	I-NP
:  	:  	 :	O
a  	a  	 DT	O
calcium-channel  	calcium-channel  	 JJ	B-NP
blocker  	blocker  	 NN	I-NP
( 	( 	 -LRB-	O
amlodipine 	amlodipine 	 LS	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
an  	an  	 DT	O
angiotensin-converting  	angiotensin-converting  	 JJ	B-NP
enzyme  	enzyme  	 NNS	I-NP
( 	( 	 -LRB-	O
ACE 	ACE 	 NNP	B-NP
) 	) 	 -RRB-	O
-inhibitor  	-inhibitor  	 NNP	O
( 	( 	 -LRB-	O
lisinopril 	lisinopril 	 LS	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
or  	or  	 CC	O
an  	an  	 DT	O
alpha-adrenergic  	alpha-adrenergic  	 JJ	B-NP
blocker  	blocker  	 NN	I-NP
( 	( 	 -LRB-	O
doxazosin 	doxazosin 	 LS	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
An  	An  	 DT	O
open-label  	open-label  	 JJ	B-NP
lipid-lowering  	lipid-lowering  	 JJ	I-NP
component  	component  	 NN	I-NP
is  	is  	 VBZ	O
designed  	designed  	 VBN	O
to  	to  	 TO	O
determine  	determine  	 VB	O
if  	if  	 IN	O
lowering  	lowering  	 VBG	B-NP
LDL  	LDL  	 NNP	I-NP
cholesterol  	cholesterol  	 NN	I-NP
with  	with  	 IN	O
pravastatin  	pravastatin  	 VBG	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
"usual  	"usual  	 CD	O
care 	care 	 NN	O
"  	"  	 ''	O
reduces  	reduces  	 VBZ	O
all-cause  	all-cause  	 JJ	B-NP
mortality  	mortality  	 NN	I-NP
in  	in  	 IN	O
a  	a  	 DT	O
subset  	subset  	 NN	B-NP
of  	of  	 IN	O
moderately  	moderately  	 RB	O
hypercholesterolemic  	hypercholesterolemic  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
Randomization  	Randomization  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
hypertension  	hypertension  	 JJ	O
component  	component  	 NN	O
began  	began  	 VBD	O
in  	in  	 IN	O
February 	February 	 NNP	O
,  	,  	 ,	O
1994 	1994 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
continued  	continued  	 VBD	O
through  	through  	 IN	O
January 	January 	 NNP	O
,  	,  	 ,	O
1998 	1998 	 CD	O
,  	,  	 ,	O
with  	with  	 IN	O
42,418  	42,418  	 CD	O
participants  	participants  	 NNS	B-NP
recruited  	recruited  	 VBN	O
at  	at  	 IN	O
623  	623  	 CD	O
clinical  	clinical  	 JJ	B-NP
centers  	centers  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
United  	United  	 NNP	B-NP
States 	States 	 NNPS	I-NP
,  	,  	 ,	O
Canada 	Canada 	 NNP	O
,  	,  	 ,	O
Puerto  	Puerto  	 NNP	O
Rico  	Rico  	 NNP	O
and  	and  	 CC	O
the  	the  	 DT	O
US  	US  	 NNP	O
Virgin  	Virgin  	 NNP	O
Islands 	Islands 	 NNPS	O
.  	.  	 .	O
Randomization  	Randomization  	 NNP	B-NP
of  	of  	 IN	O
10,355  	10,355  	 CD	O
participants  	participants  	 NNS	B-NP
into  	into  	 IN	O
the  	the  	 DT	O
lipid  	lipid  	 JJ	B-NP
trial  	trial  	 NN	I-NP
ended  	ended  	 VBD	O
May  	May  	 NNP	O
31 	31 	 CD	O
,  	,  	 ,	O
1998 	1998 	 CD	O
.  	.  	 .	O
Follow-up  	Follow-up  	 JJ	O
on  	on  	 IN	O
all  	all  	 DT	O
participants  	participants  	 NNS	B-NP
continued  	continued  	 VBD	O
through  	through  	 IN	O
March 	March 	 NNP	O
,  	,  	 ,	O
2002  	2002  	 CD	O
[  	[  	 -LRB-	O
1  	1  	 LS	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Following  	Following  	 VBG	O
independent  	independent  	 JJ	O
reviews  	reviews  	 NNS	O
by  	by  	 IN	O
the  	the  	 DT	O
Data  	Data  	 NNP	O
and  	and  	 CC	O
Safety  	Safety  	 NNP	O
Monitoring  	Monitoring  	 NNP	B-NP
Board  	Board  	 NNP	I-NP
( 	( 	 -LRB-	O
DSMB 	DSMB 	 NNP	O
)  	)  	 -RRB-	O
on  	on  	 IN	O
January  	January  	 NNP	O
6 	6 	 CD	O
,  	,  	 ,	O
2000 	2000 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
by  	by  	 IN	O
an  	an  	 DT	O
Ad  	Ad  	 NNP	B-NP
Hoc  	Hoc  	 NNP	I-NP
Committee  	Committee  	 NNP	I-NP
on  	on  	 IN	O
January  	January  	 NNP	O
21 	21 	 CD	O
,  	,  	 ,	O
2000 	2000 	 CD	O
,  	,  	 ,	O
the  	the  	 DT	O
Director  	Director  	 NNP	O
of  	of  	 IN	O
the  	the  	 DT	O
National  	National  	 NNP	B-NP
Heart 	Heart 	 NNP	I-NP
,  	,  	 ,	O
Lung 	Lung 	 NNP	O
,  	,  	 ,	O
and  	and  	 CC	O
Blood  	Blood  	 NNP	O
Institute  	Institute  	 NNP	O
accepted  	accepted  	 VBD	O
a  	a  	 DT	O
recommendation  	recommendation  	 NN	B-NP
to  	to  	 TO	O
discontinue  	discontinue  	 VB	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
arm  	arm  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
antihypertensive  	antihypertensive  	 JJ	I-NP
trial 	trial 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
recommendation  	recommendation  	 NN	B-NP
was  	was  	 VBD	O
based  	based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
low  	low  	 JJ	O
probability  	probability  	 NN	B-NP
of  	of  	 IN	I-NP
doxazosin  	doxazosin  	 JJ	I-NP
showing  	showing  	 NN	I-NP
benefit  	benefit  	 NN	I-NP
over  	over  	 IN	O
chlorthalidone  	chlorthalidone  	 NN	B-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
primary  	primary  	 JJ	I-NP
endpoint 	endpoint 	 NN	I-NP
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 IN	O
the  	the  	 DT	O
significantly  	significantly  	 RB	O
increased  	increased  	 VBD	B-NP
occurrence  	occurrence  	 VBN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
secondary  	secondary  	 JJ	I-NP
endpoint 	endpoint 	 NN	I-NP
,  	,  	 ,	O
combined  	combined  	 VBN	O
cardiovascular  	cardiovascular  	 JJ	B-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
CVD 	CVD 	 NNP	B-NP
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
encompassing  	encompassing  	 FW	B-NP
CHD  	CHD  	 FW	I-NP
deaths 	deaths 	 NNS	I-NP
,  	,  	 ,	O
nonfatal  	nonfatal  	 VBG	O
MI 	MI 	 NNP	O
,  	,  	 ,	O
stroke 	stroke 	 NN	O
,  	,  	 ,	O
coronary  	coronary  	 JJ	B-NP
revascularization  	revascularization  	 JJ	I-NP
procedures  	procedures  	 NNS	I-NP
[ 	[ 	 -LRB-	O
coronary  	coronary  	 FW	B-NP
artery  	artery  	 FW	I-NP
bypass  	bypass  	 FW	I-NP
graft  	graft  	 FW	I-NP
or  	or  	 CC	O
CABG 	CABG 	 NNP	B-NP
,  	,  	 ,	O
percutaneous  	percutaneous  	 FW	B-NP
transluminal  	transluminal  	 FW	I-NP
coronary  	coronary  	 FW	I-NP
angioplasty  	angioplasty  	 FW	I-NP
or  	or  	 FW	O
PTCA 	PTCA 	 FW	B-NP
/ 	/ 	 FW	I-NP
stent 	stent 	 FW	I-NP
] 	] 	 -RRB-	O
,  	,  	 ,	O
angina  	angina  	 NNS	O
[ 	[ 	 -LRB-	O
hospitalized  	hospitalized  	 VBN	O
or  	or  	 CC	O
treated  	treated  	 VBN	O
as  	as  	 IN	O
an  	an  	 DT	O
outpatient 	outpatient 	 NN	O
] 	] 	 -RRB-	O
,  	,  	 ,	O
heart  	heart  	 NN	B-NP
failure  	failure  	 NN	I-NP
[ 	[ 	 -LRB-	O
HF 	HF 	 NNP	O
/ 	/ 	 NNP	O
treated  	treated  	 VBD	O
in  	in  	 IN	O
the  	the  	 DT	O
hospital  	hospital  	 NN	O
or  	or  	 CC	O
as  	as  	 IN	O
an  	an  	 DT	O
outpatient 	outpatient 	 NN	O
] 	] 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
peripheral  	peripheral  	 JJ	B-NP
arterial  	arterial  	 JJ	I-NP
disease  	disease  	 NN	I-NP
[ 	[ 	 -LRB-	O
in-hospital  	in-hospital  	 NNP	B-NP
or  	or  	 CC	O
outpatient  	outpatient  	 JJ	B-NP
revascularization 	revascularization 	 NN	I-NP
] 	] 	 -RRB-	O
)  	)  	 -RRB-	O
in  	in  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
arm  	arm  	 NN	I-NP
( 	( 	 -LRB-	O
RR  	RR  	 NNP	B-NP
1.25 	1.25 	 CD	O
;  	;  	 :	O
95 	95 	 CD	O
%  	%  	 NN	O
CI 	CI 	 NNP	O
,  	,  	 ,	O
1.17-1.33 	1.17-1.33 	 NNP	O
;  	;  	 :	O
P  	P  	 NNP	O
< 	< 	 SYM	O
.001 	.001 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
with  	with  	 IN	O
a  	a  	 DT	O
doubling  	doubling  	 NN	O
of  	of  	 IN	O
risk  	risk  	 NN	O
of  	of  	 IN	O
HF  	HF  	 NNP	B-NP
( 	( 	 -LRB-	O
fatal 	fatal 	 JJ	O
,  	,  	 ,	O
hospitalized  	hospitalized  	 VBN	O
and  	and  	 CC	O
treated  	treated  	 VBN	O
but  	but  	 CC	O
nonhospitalized 	nonhospitalized 	 CD	O
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
RR  	RR  	 NNP	B-NP
2.04 	2.04 	 CD	O
;  	;  	 :	O
95 	95 	 CD	O
%  	%  	 NN	O
CI 	CI 	 NNP	O
,  	,  	 ,	O
1.79-2.32 	1.79-2.32 	 NNP	O
;  	;  	 :	O
P  	P  	 NNP	O
< 	< 	 SYM	O
.001 	.001 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
When  	When  	 WRB	O
only  	only  	 RB	O
fatal  	fatal  	 JJ	O
and  	and  	 CC	O
hospitalized  	hospitalized  	 VBN	B-NP
HF  	HF  	 NNP	I-NP
were  	were  	 VBD	O
analyzed 	analyzed 	 VBN	O
,  	,  	 ,	O
the  	the  	 DT	O
large  	large  	 JJ	O
difference  	difference  	 NN	O
remained  	remained  	 VBD	O
( 	( 	 -LRB-	O
RR  	RR  	 NNP	B-NP
1.83 	1.83 	 CD	O
;  	;  	 :	O
95 	95 	 CD	O
%  	%  	 NN	O
CI 	CI 	 NNP	O
,  	,  	 ,	O
1.58-2.13 	1.58-2.13 	 NNP	O
;  	;  	 :	O
P  	P  	 NNP	O
< 	< 	 SYM	O
.001 	.001 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
findings  	findings  	 NNS	O
and  	and  	 CC	O
operational  	operational  	 JJ	B-NP
aspects  	aspects  	 NNS	I-NP
of  	of  	 IN	O
stopping  	stopping  	 VBG	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
arm  	arm  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
study  	study  	 NN	O
have  	have  	 VBP	O
been  	been  	 VBN	O
previously  	previously  	 RB	O
described  	described  	 VBN	O
[  	[  	 -LRB-	O
2  	2  	 CD	O
3  	3  	 CD	O
4  	4  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
observed  	observed  	 JJ	O
increase  	increase  	 NN	O
in  	in  	 IN	O
HF  	HF  	 NNP	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
group  	group  	 NN	I-NP
as  	as  	 IN	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
group  	group  	 NN	I-NP
led  	led  	 VBD	O
to  	to  	 TO	O
several  	several  	 JJ	O
additional  	additional  	 JJ	O
analyses  	analyses  	 NNS	O
aimed  	aimed  	 VBN	O
toward  	toward  	 IN	O
validation  	validation  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
diagnoses 	diagnoses 	 NN	O
,  	,  	 ,	O
with  	with  	 IN	O
a  	a  	 DT	O
focus  	focus  	 NN	O
on  	on  	 IN	O
hospitalized  	hospitalized  	 NN	O
and  	and  	 CC	O
fatal  	fatal  	 JJ	B-NP
HF 	HF 	 NNP	I-NP
.  	.  	 .	O
The  	The  	 DT	O
purposes  	purposes  	 NNS	O
of  	of  	 IN	O
these  	these  	 DT	O
analyses  	analyses  	 NNS	O
were 	were 	 VBD	O
:  	:  	 :	O
1 	1 	 LS	O
)  	)  	 -RRB-	O
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
reality  	reality  	 NN	O
of  	of  	 IN	O
HF  	HF  	 NNP	B-NP
cases 	cases 	 NNS	I-NP
,  	,  	 ,	O
i.e.  	i.e.  	 FW	O
whether  	whether  	 IN	O
diagnosis 	diagnosis 	 NN	O
,  	,  	 ,	O
management 	management 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
clinical  	clinical  	 JJ	B-NP
course  	course  	 NN	I-NP
were  	were  	 VBD	O
what  	what  	 WP	O
might  	might  	 MD	O
be  	be  	 VB	O
expected 	expected 	 VBN	O
,  	,  	 ,	O
and  	and  	 CC	O
2 	2 	 LS	O
)  	)  	 -RRB-	O
to  	to  	 TO	O
compare  	compare  	 VB	O
these  	these  	 DT	O
features  	features  	 NNS	O
between  	between  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
treatment  	treatment  	 NN	B-NP
groups 	groups 	 NNS	I-NP
.  	.  	 .	O
Methods  	Methods  	 NNP	O
Study  	Study  	 NNP	O
Design  	Design  	 NNP	O
The  	The  	 DT	O
rationale  	rationale  	 NN	O
and  	and  	 CC	O
design  	design  	 NN	O
of  	of  	 IN	O
ALLHAT  	ALLHAT  	 NNP	B-NP
are  	are  	 VBP	O
described  	described  	 VBN	O
in  	in  	 IN	O
detail  	detail  	 NN	O
elsewhere  	elsewhere  	 RB	O
[  	[  	 -LRB-	O
1  	1  	 LS	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Briefly 	Briefly 	 RB	O
,  	,  	 ,	O
those  	those  	 DT	O
eligible  	eligible  	 NN	O
for  	for  	 IN	O
randomization  	randomization  	 NN	B-NP
had  	had  	 VBD	O
systolic  	systolic  	 JJ	B-NP
blood  	blood  	 NN	I-NP
pressure  	pressure  	 NN	I-NP
( 	( 	 -LRB-	O
SBP 	SBP 	 NNP	B-NP
)  	)  	 -RRB-	O
of  	of  	 IN	O
at  	at  	 IN	O
least  	least  	 JJS	O
140  	140  	 CD	O
mm  	mm  	 JJ	B-NP
Hg  	Hg  	 NNP	I-NP
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
diastolic  	diastolic  	 JJ	B-NP
blood  	blood  	 NN	I-NP
pressure  	pressure  	 NN	I-NP
of  	of  	 IN	O
at  	at  	 IN	O
least  	least  	 JJS	O
90  	90  	 CD	O
mm  	mm  	 JJ	B-NP
Hg 	Hg 	 NNP	I-NP
,  	,  	 ,	O
or  	or  	 CC	O
took  	took  	 VBD	O
medication  	medication  	 NN	O
for  	for  	 IN	O
hypertension 	hypertension 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
had  	had  	 VBD	O
at  	at  	 IN	O
least  	least  	 JJS	O
one  	one  	 CD	O
other  	other  	 JJ	O
risk  	risk  	 NN	B-NP
factor  	factor  	 NN	I-NP
for  	for  	 IN	I-NP
CHD  	CHD  	 NNP	I-NP
events 	events 	 NNS	I-NP
.  	.  	 .	O
Risk  	Risk  	 NN	B-NP
factors  	factors  	 NNS	I-NP
included  	included  	 VBD	O
previous  	previous  	 JJ	O
MI  	MI  	 NNP	O
or  	or  	 CC	O
stroke 	stroke 	 NN	O
,  	,  	 ,	O
left  	left  	 VBD	O
ventricular  	ventricular  	 JJ	B-NP
hypertrophy  	hypertrophy  	 NN	I-NP
by  	by  	 IN	O
electrocardiogram  	electrocardiogram  	 NN	O
or  	or  	 CC	O
echocardiogram 	echocardiogram 	 NN	B-NP
,  	,  	 ,	O
history  	history  	 NN	O
of  	of  	 IN	O
type  	type  	 NN	O
2  	2  	 CD	O
diabetes 	diabetes 	 NN	O
,  	,  	 ,	O
current  	current  	 JJ	O
cigarette  	cigarette  	 NN	O
smoking 	smoking 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
low  	low  	 JJ	O
high-density  	high-density  	 JJ	B-NP
lipoprotein  	lipoprotein  	 NNS	I-NP
( 	( 	 -LRB-	O
HDL 	HDL 	 NNP	B-NP
)  	)  	 -RRB-	O
level 	level 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
primary  	primary  	 JJ	B-NP
endpoint  	endpoint  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
blood  	blood  	 NN	B-NP
pressure  	pressure  	 NN	I-NP
( 	( 	 -LRB-	O
BP 	BP 	 NNP	B-NP
)  	)  	 -RRB-	O
trial  	trial  	 NN	O
is  	is  	 VBZ	O
the  	the  	 DT	O
composite  	composite  	 JJ	O
of  	of  	 IN	O
nonfatal  	nonfatal  	 JJ	B-NP
MI  	MI  	 NNP	I-NP
and  	and  	 CC	O
fatal  	fatal  	 JJ	B-NP
CHD 	CHD 	 NNP	I-NP
.  	.  	 .	O
The  	The  	 DT	O
four  	four  	 CD	O
protocol-defined  	protocol-defined  	 JJ	B-NP
secondary  	secondary  	 JJ	I-NP
clinical  	clinical  	 JJ	I-NP
outcomes  	outcomes  	 NNS	I-NP
are  	are  	 VBP	O
all-cause  	all-cause  	 JJ	B-NP
mortality 	mortality 	 NN	I-NP
,  	,  	 ,	O
combined  	combined  	 VBN	O
CHD  	CHD  	 NNP	B-NP
( 	( 	 -LRB-	O
including  	including  	 VBG	B-NP
CHD  	CHD  	 NNP	I-NP
death 	death 	 NN	I-NP
,  	,  	 ,	O
nonfatal  	nonfatal  	 VBG	O
MI 	MI 	 NNP	O
,  	,  	 ,	O
coronary  	coronary  	 JJ	B-NP
revascularization  	revascularization  	 JJ	I-NP
procedures  	procedures  	 NNS	I-NP
and  	and  	 CC	O
hospitalized  	hospitalized  	 JJ	O
angina 	angina 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
stroke 	stroke 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
combined  	combined  	 JJ	O
CVD  	CVD  	 NNP	B-NP
( 	( 	 -LRB-	O
including  	including  	 VBG	B-NP
CHD  	CHD  	 NNP	I-NP
death 	death 	 NN	I-NP
,  	,  	 ,	O
nonfatal  	nonfatal  	 VBG	O
MI 	MI 	 NNP	O
,  	,  	 ,	O
stroke 	stroke 	 NN	O
,  	,  	 ,	O
coronary  	coronary  	 JJ	B-NP
revascularization  	revascularization  	 JJ	I-NP
procedures 	procedures 	 NNS	I-NP
,  	,  	 ,	O
angina  	angina  	 VBD	O
treated  	treated  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
hospital  	hospital  	 NN	O
or  	or  	 CC	O
as  	as  	 IN	O
an  	an  	 DT	O
outpatient 	outpatient 	 NN	O
,  	,  	 ,	O
lower  	lower  	 JJR	O
extremity  	extremity  	 JJ	O
peripheral  	peripheral  	 JJ	B-NP
arterial  	arterial  	 JJ	I-NP
disease  	disease  	 NN	I-NP
treated  	treated  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
hospital  	hospital  	 NN	O
or  	or  	 CC	O
with  	with  	 IN	O
outpatient  	outpatient  	 JJ	B-NP
revascularization 	revascularization 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
HF 	HF 	 NNP	B-NP
,  	,  	 ,	O
fatal  	fatal  	 JJ	O
or  	or  	 CC	O
treated  	treated  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
hospital  	hospital  	 NN	O
or  	or  	 CC	O
as  	as  	 IN	O
an  	an  	 DT	O
outpatient 	outpatient 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
validation  	validation  	 NN	B-NP
of  	of  	 IN	I-NP
HF  	HF  	 NNP	I-NP
diagnosis  	diagnosis  	 VBD	I-NP
entailed  	entailed  	 VBN	O
answering  	answering  	 VBG	O
several  	several  	 JJ	O
questions 	questions 	 NNS	O
:  	:  	 :	O
1 	1 	 LS	O
.  	.  	 .	O
Did  	Did  	 VBD	O
HF  	HF  	 NNP	B-NP
cases  	cases  	 NNS	I-NP
meet  	meet  	 VBP	O
ALLHAT  	ALLHAT  	 JJ	B-NP
diagnostic  	diagnostic  	 JJ	I-NP
criteria 	criteria 	 NNS	I-NP
?  	?  	 .	O
2 	2 	 LS	O
.  	.  	 .	O
Were  	Were  	 VBD	O
baseline  	baseline  	 JJ	B-NP
characteristics  	characteristics  	 NNS	I-NP
and  	and  	 CC	O
medical  	medical  	 JJ	B-NP
management  	management  	 NN	I-NP
for  	for  	 IN	I-NP
HF  	HF  	 NNP	I-NP
cases  	cases  	 NNS	I-NP
as  	as  	 RB	O
expected  	expected  	 VBN	O
and  	and  	 CC	O
similar  	similar  	 JJ	O
across  	across  	 IN	O
the  	the  	 DT	O
drug  	drug  	 NN	B-NP
groups 	groups 	 NNS	I-NP
?  	?  	 .	O
3 	3 	 LS	O
.  	.  	 .	O
Were  	Were  	 VBD	O
prevalence  	prevalence  	 JJ	O
and  	and  	 CC	O
severity  	severity  	 NN	O
of  	of  	 IN	O
systolic  	systolic  	 JJ	O
dysfunction  	dysfunction  	 NN	O
as  	as  	 IN	O
expected  	expected  	 VBN	O
and  	and  	 CC	O
similar  	similar  	 JJ	O
across  	across  	 IN	O
drug  	drug  	 NN	O
groups 	groups 	 NNS	O
?  	?  	 .	O
4 	4 	 LS	O
.  	.  	 .	O
Were  	Were  	 VBD	O
case-fatality  	case-fatality  	 JJ	O
rates  	rates  	 NNS	O
as  	as  	 RB	O
expected  	expected  	 VBN	O
and  	and  	 CC	O
similar  	similar  	 JJ	O
across  	across  	 IN	O
drug  	drug  	 NN	O
groups 	groups 	 NNS	O
?  	?  	 .	O
Unless  	Unless  	 IN	O
otherwise  	otherwise  	 RB	O
specified 	specified 	 VBN	O
,  	,  	 ,	O
all  	all  	 DT	O
data  	data  	 NNS	O
for  	for  	 IN	O
these  	these  	 DT	O
analyses  	analyses  	 NNS	O
were  	were  	 VBD	O
collected  	collected  	 VBN	O
as  	as  	 IN	O
of  	of  	 IN	O
December 	December 	 NNP	O
,  	,  	 ,	O
1999 	1999 	 CD	O
.  	.  	 .	O
Heart  	Heart  	 NNP	B-NP
Failure  	Failure  	 NNP	I-NP
Diagnosis  	Diagnosis  	 NNP	I-NP
At  	At  	 IN	O
each  	each  	 DT	O
follow-up  	follow-up  	 JJ	B-NP
clinic  	clinic  	 NN	I-NP
visit  	visit  	 NN	I-NP
the  	the  	 DT	O
occurrence  	occurrence  	 NN	O
of  	of  	 IN	O
study  	study  	 NN	O
clinical  	clinical  	 JJ	B-NP
events  	events  	 NNS	I-NP
was  	was  	 VBD	O
assessed 	assessed 	 VBN	O
,  	,  	 ,	O
and 	and 	 CC	O
,  	,  	 ,	O
if  	if  	 IN	O
identified  	identified  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
investigator 	investigator 	 NN	I-NP
,  	,  	 ,	O
reported  	reported  	 VBD	O
on  	on  	 IN	O
an  	an  	 DT	O
endpoint  	endpoint  	 JJ	B-NP
form 	form 	 NN	I-NP
.  	.  	 .	O
For  	For  	 IN	O
each  	each  	 DT	O
event  	event  	 NN	O
involving  	involving  	 VBG	B-NP
hospitalization 	hospitalization 	 NN	I-NP
,  	,  	 ,	O
a  	a  	 DT	O
hospital  	hospital  	 NN	B-NP
discharge  	discharge  	 NN	I-NP
summary  	summary  	 NN	I-NP
or  	or  	 CC	O
expiration  	expiration  	 NN	B-NP
summary  	summary  	 NN	I-NP
was  	was  	 VBD	O
to  	to  	 TO	O
be  	be  	 VB	O
submitted 	submitted 	 VBN	O
,  	,  	 ,	O
and  	and  	 CC	O
for  	for  	 IN	O
each  	each  	 DT	O
death  	death  	 NN	O
a  	a  	 DT	O
death  	death  	 NN	B-NP
certificate  	certificate  	 NN	I-NP
was  	was  	 VBD	O
required 	required 	 VBN	O
.  	.  	 .	O
Endpoint  	Endpoint  	 JJ	B-NP
forms  	forms  	 NNS	I-NP
and  	and  	 CC	O
supporting  	supporting  	 VBG	O
documentation  	documentation  	 NNS	B-NP
were  	were  	 VBD	O
reviewed  	reviewed  	 VBN	O
at  	at  	 IN	O
the  	the  	 DT	O
ALLHAT  	ALLHAT  	 NNP	B-NP
Clinical  	Clinical  	 NNP	I-NP
Trials  	Trials  	 NNP	I-NP
Center  	Center  	 NNP	O
( 	( 	 -LRB-	O
CTC 	CTC 	 NNP	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
accuracy  	accuracy  	 NN	B-NP
and  	and  	 CC	O
appropriateness 	appropriateness 	 NN	B-NP
.  	.  	 .	O
When  	When  	 WRB	O
a  	a  	 DT	O
discrepancy  	discrepancy  	 NN	O
or  	or  	 CC	O
ambiguity  	ambiguity  	 NN	B-NP
was  	was  	 VBD	O
found 	found 	 VBN	O
,  	,  	 ,	O
the  	the  	 DT	O
CTC  	CTC  	 NNP	B-NP
sent  	sent  	 VBD	O
a  	a  	 DT	O
written  	written  	 JJ	O
query  	query  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
Principal  	Principal  	 NNP	B-NP
Investigator 	Investigator 	 NNP	I-NP
,  	,  	 ,	O
who  	who  	 WP	O
retained  	retained  	 VBD	O
the  	the  	 DT	O
final  	final  	 JJ	B-NP
word  	word  	 NN	I-NP
concerning  	concerning  	 VBG	O
the  	the  	 DT	O
diagnosis  	diagnosis  	 NN	O
or  	or  	 CC	O
cause  	cause  	 NN	O
of  	of  	 IN	O
death 	death 	 NN	O
.  	.  	 .	O
A  	A  	 DT	O
random  	random  	 JJ	O
10 	10 	 CD	O
%  	%  	 NN	O
sample  	sample  	 NN	O
of  	of  	 IN	O
strokes 	strokes 	 NNS	O
,  	,  	 ,	O
nonfatal  	nonfatal  	 JJ	B-NP
MIs  	MIs  	 JJ	I-NP
and  	and  	 CC	O
CHD  	CHD  	 NNP	B-NP
deaths  	deaths  	 NNS	I-NP
was  	was  	 VBD	O
selected  	selected  	 VBN	O
for  	for  	 IN	O
blinded  	blinded  	 JJ	O
quality  	quality  	 NN	B-NP
control  	control  	 NN	I-NP
evaluation  	evaluation  	 NN	I-NP
by  	by  	 IN	O
the  	the  	 DT	O
ALLHAT  	ALLHAT  	 NNP	B-NP
Endpoints  	Endpoints  	 NNP	I-NP
Subcommittee 	Subcommittee 	 NNP	O
;  	;  	 :	O
for  	for  	 IN	O
these  	these  	 DT	O
cases  	cases  	 NNS	O
additional  	additional  	 JJ	O
documentation  	documentation  	 NN	B-NP
was  	was  	 VBD	O
requested 	requested 	 VBN	O
.  	.  	 .	O
No  	No  	 DT	O
such  	such  	 JJ	O
routine  	routine  	 JJ	B-NP
Endpoints  	Endpoints  	 NNP	I-NP
Subcommittee  	Subcommittee  	 NNP	I-NP
quality  	quality  	 NN	I-NP
control  	control  	 NN	I-NP
was  	was  	 VBD	O
initially  	initially  	 RB	O
planned  	planned  	 VBN	O
for  	for  	 IN	O
reported  	reported  	 VBN	B-NP
HF 	HF 	 NNP	I-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
Subcommittee  	Subcommittee  	 NNP	O
was  	was  	 VBD	O
subsequently  	subsequently  	 RB	O
called  	called  	 VBN	O
upon  	upon  	 RP	O
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
a  	a  	 DT	O
random  	random  	 JJ	O
sample  	sample  	 NN	O
of  	of  	 IN	O
reported  	reported  	 VBN	O
fatal  	fatal  	 JJ	O
and  	and  	 CC	O
hospitalized  	hospitalized  	 VBN	O
nonfatal  	nonfatal  	 JJ	B-NP
HF  	HF  	 NN	I-NP
events 	events 	 NNS	I-NP
.  	.  	 .	O
As  	As  	 IN	O
this  	this  	 DT	O
occurred  	occurred  	 VBD	O
prior  	prior  	 RB	O
to  	to  	 TO	O
the  	the  	 DT	O
termination  	termination  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
arm 	arm 	 NN	I-NP
,  	,  	 ,	O
neither  	neither  	 CC	O
the  	the  	 DT	O
chair  	chair  	 NN	O
nor  	nor  	 CC	O
the  	the  	 DT	O
members  	members  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
Subcommittee  	Subcommittee  	 NNP	O
was  	was  	 VBD	O
informed  	informed  	 VBN	O
of  	of  	 IN	O
the  	the  	 DT	O
major  	major  	 JJ	O
reason  	reason  	 NN	O
for  	for  	 IN	O
this  	this  	 DT	O
review 	review 	 NN	O
,  	,  	 ,	O
namely 	namely 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
trend  	trend  	 NN	O
toward  	toward  	 IN	O
a  	a  	 DT	O
higher  	higher  	 JJR	O
HF  	HF  	 JJ	B-NP
event  	event  	 NN	I-NP
rate  	rate  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
group  	group  	 NN	I-NP
compared  	compared  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
group 	group 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
Subcommittee  	Subcommittee  	 NNP	O
was  	was  	 VBD	O
told  	told  	 VBN	O
that  	that  	 IN	O
the  	the  	 DT	O
review  	review  	 NN	O
was  	was  	 VBD	O
undertaken  	undertaken  	 VBN	O
at  	at  	 IN	O
the  	the  	 DT	O
request  	request  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
DSMB  	DSMB  	 NNP	B-NP
to  	to  	 TO	O
address  	address  	 VB	O
the  	the  	 DT	O
reliability  	reliability  	 NN	O
and  	and  	 CC	O
validity  	validity  	 NN	O
of  	of  	 IN	O
reported  	reported  	 VBN	B-NP
HF  	HF  	 NNP	I-NP
events 	events 	 NNS	I-NP
.  	.  	 .	O
This  	This  	 DT	O
evaluation  	evaluation  	 NN	O
consisted  	consisted  	 VBD	O
of  	of  	 IN	O
fifty  	fifty  	 JJ	O
events 	events 	 NNS	O
,  	,  	 ,	O
evenly  	evenly  	 RB	O
distributed  	distributed  	 VBN	O
across  	across  	 IN	O
the  	the  	 DT	O
four  	four  	 CD	O
treatment  	treatment  	 NN	B-NP
groups 	groups 	 NNS	I-NP
,  	,  	 ,	O
reported  	reported  	 VBD	O
as  	as  	 IN	O
fatal  	fatal  	 JJ	O
or  	or  	 CC	O
hospitalized  	hospitalized  	 VBN	O
nonfatal  	nonfatal  	 JJ	B-NP
HF  	HF  	 NNP	I-NP
and  	and  	 CC	O
with  	with  	 IN	O
protocol-required  	protocol-required  	 JJ	B-NP
documentation  	documentation  	 NNS	I-NP
( 	( 	 -LRB-	O
discharge  	discharge  	 JJ	B-NP
summary  	summary  	 NN	I-NP
for  	for  	 IN	O
hospitalized  	hospitalized  	 JJ	O
events 	events 	 NNS	O
,  	,  	 ,	O
death  	death  	 NN	B-NP
certificates  	certificates  	 NNS	I-NP
for  	for  	 IN	O
deaths 	deaths 	 NNS	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Additional  	Additional  	 JJ	O
material  	material  	 NN	O
was  	was  	 VBD	O
not  	not  	 RB	O
requested 	requested 	 VBN	O
,  	,  	 ,	O
since  	since  	 IN	O
this  	this  	 DT	O
would  	would  	 MD	O
have  	have  	 VB	O
posed  	posed  	 VBN	O
an  	an  	 DT	O
undue  	undue  	 JJ	O
burden  	burden  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
site  	site  	 NN	I-NP
staff  	staff  	 NN	I-NP
and  	and  	 CC	O
would  	would  	 MD	O
have  	have  	 VB	O
risked  	risked  	 VBN	O
raising  	raising  	 VBG	B-NP
questions  	questions  	 NNS	I-NP
about  	about  	 IN	O
emerging  	emerging  	 VBG	B-NP
differences  	differences  	 NNS	I-NP
among  	among  	 IN	O
treatment  	treatment  	 NN	B-NP
groups 	groups 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
ALLHAT  	ALLHAT  	 NNP	B-NP
definition  	definition  	 NN	I-NP
of  	of  	 IN	I-NP
HF 	HF 	 NNP	I-NP
,  	,  	 ,	O
used  	used  	 VBN	O
previously  	previously  	 RB	O
in  	in  	 IN	O
the  	the  	 DT	O
Systolic  	Systolic  	 NNP	B-NP
Hypertension  	Hypertension  	 NNP	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
Elderly  	Elderly  	 JJ	O
Program  	Program  	 NN	O
( 	( 	 -LRB-	O
SHEP 	SHEP 	 NNP	B-NP
)  	)  	 -RRB-	O
[  	[  	 -LRB-	O
5  	5  	 LS	O
]  	]  	 -RRB-	O
,  	,  	 ,	O
includes  	includes  	 VBZ	O
"patients  	"patients  	 CD	O
with  	with  	 IN	O
clear-cut  	clear-cut  	 JJ	B-NP
signs  	signs  	 NNS	I-NP
or  	or  	 CC	O
symptoms  	symptoms  	 NNS	B-NP
of  	of  	 IN	O
left  	left  	 VBN	O
or  	or  	 CC	O
right  	right  	 RB	O
ventricular  	ventricular  	 JJ	B-NP
dysfunction  	dysfunction  	 NN	I-NP
that  	that  	 WDT	O
cannot  	cannot  	 RB	O
be  	be  	 VB	O
attributed  	attributed  	 VBN	O
to  	to  	 TO	O
other  	other  	 JJ	O
causes... 	causes... 	 NN	O
"  	"  	 ''	O
The  	The  	 DT	O
diagnosis  	diagnosis  	 NN	O
of  	of  	 IN	O
HF  	HF  	 NNP	B-NP
must  	must  	 MD	O
include  	include  	 VB	O
at  	at  	 IN	O
least  	least  	 JJS	O
one  	one  	 CD	O
of  	of  	 IN	O
four  	four  	 CD	O
stated  	stated  	 JJ	O
symptoms  	symptoms  	 NNS	B-NP
[ 	[ 	 -LRB-	O
paroxysmal  	paroxysmal  	 FW	B-NP
nocturnal  	nocturnal  	 FW	I-NP
dyspnea 	dyspnea 	 FW	I-NP
,  	,  	 ,	O
dyspnea  	dyspnea  	 VBG	O
at  	at  	 IN	O
rest 	rest 	 NN	O
,  	,  	 ,	O
New  	New  	 NNP	B-NP
York  	York  	 NNP	I-NP
Heart  	Heart  	 NNP	I-NP
Classification  	Classification  	 NNP	I-NP
functional  	functional  	 JJ	I-NP
class  	class  	 NN	I-NP
III  	III  	 NNP	I-NP
( 	( 	 -LRB-	O
for  	for  	 IN	O
definition  	definition  	 NN	O
see  	see  	 VBP	O
Additional  	Additional  	 JJ	B-NP
Information 	Information 	 NNP	I-NP
,  	,  	 ,	O
Item  	Item  	 NNP	O
1 	1 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
or  	or  	 CC	O
orthopnea 	orthopnea 	 CD	B-NP
] 	] 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
one  	one  	 CD	O
of  	of  	 IN	O
seven  	seven  	 CD	O
stated  	stated  	 JJ	O
signs  	signs  	 NNS	O
( 	( 	 -LRB-	O
rales 	rales 	 UH	O
,  	,  	 ,	O
2+  	2+  	 NNP	O
or  	or  	 CC	O
greater  	greater  	 JJR	O
ankle  	ankle  	 JJ	B-NP
edema 	edema 	 NN	I-NP
,  	,  	 ,	O
tachycardia  	tachycardia  	 NN	B-NP
of  	of  	 IN	O
120  	120  	 CD	O
beats 	beats 	 CD	B-NP
/ 	/ 	 CD	I-NP
minute  	minute  	 NN	I-NP
or  	or  	 CC	O
more  	more  	 JJR	O
after  	after  	 IN	O
five  	five  	 CD	O
minutes  	minutes  	 NNS	O
at  	at  	 IN	O
rest 	rest 	 NN	O
,  	,  	 ,	O
cardiomegaly  	cardiomegaly  	 VBG	O
by  	by  	 IN	O
chest  	chest  	 JJ	B-NP
x-ray 	x-ray 	 NN	I-NP
,  	,  	 ,	O
chest  	chest  	 JJ	B-NP
x-ray  	x-ray  	 JJ	I-NP
characteristic  	characteristic  	 NN	I-NP
of  	of  	 IN	I-NP
HF 	HF 	 NNP	I-NP
,  	,  	 ,	O
S  	S  	 NNP	O
3  	3  	 CD	O
gallop 	gallop 	 NN	O
,  	,  	 ,	O
or  	or  	 CC	O
jugular  	jugular  	 FW	B-NP
venous  	venous  	 FW	I-NP
distention 	distention 	 FW	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Since  	Since  	 IN	O
lower  	lower  	 JJR	O
extremity  	extremity  	 JJ	B-NP
edema  	edema  	 NN	I-NP
or  	or  	 CC	O
exertional  	exertional  	 JJ	B-NP
dyspnea  	dyspnea  	 NN	I-NP
may  	may  	 MD	O
be  	be  	 VB	O
due  	due  	 JJ	O
to  	to  	 TO	O
non-cardiac  	non-cardiac  	 JJ	B-NP
causes 	causes 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
presence  	presence  	 NN	O
of  	of  	 IN	O
either  	either  	 RB	O
of  	of  	 IN	O
these  	these  	 DT	O
alone 	alone 	 RB	O
,  	,  	 ,	O
without  	without  	 IN	O
other  	other  	 JJ	O
indications  	indications  	 NNS	O
of  	of  	 IN	O
heart  	heart  	 NN	B-NP
failure 	failure 	 NN	I-NP
,  	,  	 ,	O
is  	is  	 VBZ	O
not  	not  	 RB	O
sufficient  	sufficient  	 JJ	O
for  	for  	 IN	O
a  	a  	 DT	O
diagnosis  	diagnosis  	 NN	O
of  	of  	 IN	O
HF 	HF 	 NNP	B-NP
.  	.  	 .	O
Study  	Study  	 NN	B-NP
guidelines  	guidelines  	 NNS	I-NP
caution  	caution  	 VBP	O
against  	against  	 IN	O
a  	a  	 DT	O
hasty  	hasty  	 JJ	O
HF  	HF  	 NNP	B-NP
diagnosis  	diagnosis  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
severe  	severe  	 JJ	O
pulmonary  	pulmonary  	 JJ	B-NP
disease 	disease 	 NN	I-NP
,  	,  	 ,	O
including  	including  	 VBG	O
chronic  	chronic  	 JJ	B-NP
obstructive  	obstructive  	 JJ	I-NP
pulmonary  	pulmonary  	 JJ	I-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
COPD 	COPD 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
pneumonia 	pneumonia 	 NN	O
,  	,  	 ,	O
or  	or  	 CC	O
other  	other  	 JJ	O
severe 	severe 	 JJ	O
,  	,  	 ,	O
documented  	documented  	 VBN	B-NP
lung  	lung  	 NN	I-NP
disease 	disease 	 NN	I-NP
.  	.  	 .	O
Baseline  	Baseline  	 NNP	B-NP
Characteristics  	Characteristics  	 NNP	I-NP
and  	and  	 CC	O
Medical  	Medical  	 NNP	B-NP
Management  	Management  	 NNP	I-NP
Baseline  	Baseline  	 NNP	I-NP
characteristics  	characteristics  	 NNS	I-NP
of  	of  	 IN	I-NP
chlorthalidone  	chlorthalidone  	 NN	I-NP
and  	and  	 CC	O
doxazosin  	doxazosin  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
were  	were  	 VBD	O
compared 	compared 	 VBN	O
.  	.  	 .	O
These  	These  	 DT	O
analyses  	analyses  	 NNS	O
were  	were  	 VBD	O
stratified  	stratified  	 VBN	O
by  	by  	 IN	O
HF  	HF  	 NNP	B-NP
outcome 	outcome 	 NN	I-NP
:  	:  	 :	O
1 	1 	 LS	O
)  	)  	 -RRB-	O
fatal  	fatal  	 JJ	O
and  	and  	 CC	O
hospitalized  	hospitalized  	 VBN	B-NP
HF 	HF 	 NNP	I-NP
;  	;  	 :	O
2 	2 	 LS	O
)  	)  	 -RRB-	O
treated 	treated 	 VBN	O
,  	,  	 ,	O
non-hospitalized  	non-hospitalized  	 NNP	B-NP
HF 	HF 	 NNP	I-NP
;  	;  	 :	O
and 	and 	 CC	O
,  	,  	 ,	O
3 	3 	 LS	O
)  	)  	 -RRB-	O
no  	no  	 DT	O
HF 	HF 	 NNP	B-NP
.  	.  	 .	O
Post-HF  	Post-HF  	 JJ	B-NP
event  	event  	 NN	I-NP
medical  	medical  	 JJ	I-NP
management  	management  	 NN	I-NP
may  	may  	 MD	O
provide  	provide  	 VB	O
additional  	additional  	 JJ	O
evidence  	evidence  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
physicians 	physicians 	 NNS	O
'  	'  	 POS	O
confidence  	confidence  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
HF  	HF  	 NNP	B-NP
diagnosis 	diagnosis 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
post-event  	post-event  	 JJ	B-NP
use  	use  	 NN	I-NP
of  	of  	 IN	I-NP
open-label  	open-label  	 JJ	I-NP
diuretics 	diuretics 	 NN	I-NP
,  	,  	 ,	O
ACE-inhibitors 	ACE-inhibitors 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
beta-blockers 	beta-blockers 	 JJ	B-NP
,  	,  	 ,	O
i.e. 	i.e. 	 FW	O
,  	,  	 ,	O
accepted  	accepted  	 VBD	B-NP
treatments  	treatments  	 NNS	I-NP
for  	for  	 IN	I-NP
HF  	HF  	 NNP	I-NP
[  	[  	 -LRB-	O
6  	6  	 CD	O
7  	7  	 CD	O
8  	8  	 CD	O
9  	9  	 CD	O
]  	]  	 -RRB-	O
,  	,  	 ,	O
was  	was  	 VBD	O
compared  	compared  	 VBN	O
between  	between  	 IN	O
doxazosin  	doxazosin  	 NN	B-NP
and  	and  	 CC	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
groups 	groups 	 NNS	I-NP
,  	,  	 ,	O
as  	as  	 RB	O
was  	was  	 VBD	O
the  	the  	 DT	O
proportion  	proportion  	 NN	O
in  	in  	 IN	O
each  	each  	 DT	O
group  	group  	 NN	O
of  	of  	 IN	O
those  	those  	 DT	O
who  	who  	 WP	O
remained  	remained  	 VBD	O
on  	on  	 IN	O
assigned  	assigned  	 VBN	O
blinded  	blinded  	 JJ	O
medication  	medication  	 NN	O
after  	after  	 IN	O
the  	the  	 DT	O
event 	event 	 NN	O
.  	.  	 .	O
( 	( 	 -LRB-	O
For  	For  	 IN	O
study  	study  	 NN	B-NP
guidelines  	guidelines  	 NNS	I-NP
regarding  	regarding  	 VBG	O
the  	the  	 DT	O
use  	use  	 NN	O
and  	and  	 CC	O
reporting  	reporting  	 VBG	O
of  	of  	 IN	O
open-label  	open-label  	 JJ	B-NP
medicines  	medicines  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
same  	same  	 JJ	O
class  	class  	 NN	O
as  	as  	 IN	O
the  	the  	 DT	O
blinded  	blinded  	 JJ	O
drugs 	drugs 	 NNS	O
,  	,  	 ,	O
see  	see  	 VBP	O
Additional  	Additional  	 JJ	B-NP
Information 	Information 	 NNP	I-NP
,  	,  	 ,	O
Items  	Items  	 NNP	O
2  	2  	 CD	O
and  	and  	 CC	O
3 	3 	 CD	O
. 	. 	 .	O
)  	)  	 -RRB-	O
Ejection  	Ejection  	 NNP	B-NP
Fraction  	Fraction  	 NNP	I-NP
Review  	Review  	 NNP	I-NP
A  	A  	 NNP	O
CTC  	CTC  	 NNP	B-NP
physician  	physician  	 NN	I-NP
plus  	plus  	 CC	O
non-medical  	non-medical  	 JJ	B-NP
staff  	staff  	 NN	I-NP
reviewed  	reviewed  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
blinded  	blinded  	 JJ	O
fashion  	fashion  	 NN	O
361  	361  	 CD	O
hospitalized  	hospitalized  	 JJ	O
HF  	HF  	 NN	B-NP
events  	events  	 NNS	I-NP
( 	( 	 -LRB-	O
representing  	representing  	 VBG	O
278  	278  	 CD	O
participants 	participants 	 NNS	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
ejection  	ejection  	 JJ	B-NP
fraction  	fraction  	 NN	I-NP
data 	data 	 NNS	I-NP
:  	:  	 :	O
looking  	looking  	 VBG	O
for  	for  	 IN	O
whether  	whether  	 IN	O
an  	an  	 DT	O
ejection  	ejection  	 JJ	B-NP
fraction  	fraction  	 NN	I-NP
was  	was  	 VBD	O
measured 	measured 	 VBN	O
,  	,  	 ,	O
the  	the  	 DT	O
method  	method  	 NN	B-NP
utilized 	utilized 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
measurement 	measurement 	 NN	O
.  	.  	 .	O
Results 	Results 	 NNS	O
,  	,  	 ,	O
tabulated  	tabulated  	 VBG	O
by  	by  	 IN	O
randomization  	randomization  	 JJ	B-NP
groups 	groups 	 NNS	I-NP
,  	,  	 ,	O
reflected  	reflected  	 VBD	O
data  	data  	 NNS	O
that  	that  	 WDT	O
had  	had  	 VBD	O
been  	been  	 VBN	O
collected  	collected  	 VBN	O
up  	up  	 RP	O
to  	to  	 TO	O
July 	July 	 NNP	O
,  	,  	 ,	O
1999 	1999 	 CD	O
,  	,  	 ,	O
the  	the  	 DT	O
time  	time  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
review 	review 	 NN	O
.  	.  	 .	O
Case-Fatality  	Case-Fatality  	 JJ	B-NP
Rates  	Rates  	 NNS	I-NP
and  	and  	 CC	O
Causes  	Causes  	 NNP	O
of  	of  	 IN	O
Death  	Death  	 NN	O
As  	As  	 IN	O
a  	a  	 DT	O
measure  	measure  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
diagnostic  	diagnostic  	 JJ	B-NP
validity  	validity  	 NN	I-NP
and  	and  	 CC	O
severity  	severity  	 NN	O
of  	of  	 IN	O
HF  	HF  	 NNP	B-NP
and  	and  	 CC	O
comparability  	comparability  	 NN	B-NP
between  	between  	 IN	O
drug  	drug  	 NN	B-NP
groups 	groups 	 NNS	I-NP
,  	,  	 ,	O
time-from-event-to-death  	time-from-event-to-death  	 JJ	B-NP
analyses  	analyses  	 NNS	I-NP
of  	of  	 IN	I-NP
participants  	participants  	 NNS	I-NP
with  	with  	 IN	O
hospitalized  	hospitalized  	 NN	O
or  	or  	 CC	O
treated  	treated  	 VBN	B-NP
HF  	HF  	 NNP	I-NP
were  	were  	 VBD	O
compared  	compared  	 VBN	O
between  	between  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
groups 	groups 	 NNS	O
.  	.  	 .	O
Causes  	Causes  	 NNS	O
of  	of  	 IN	O
death  	death  	 NN	O
of  	of  	 IN	O
such  	such  	 JJ	O
participants  	participants  	 NNS	B-NP
were  	were  	 VBD	O
also  	also  	 RB	O
compared  	compared  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 NN	B-NP
and  	and  	 CC	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
groups 	groups 	 NNS	I-NP
.  	.  	 .	O
Statistical  	Statistical  	 NNP	B-NP
Analyses  	Analyses  	 NNP	I-NP
Data  	Data  	 NNP	O
were  	were  	 VBD	O
analyzed  	analyzed  	 VBN	O
according  	according  	 VBG	O
to  	to  	 TO	O
participants 	participants 	 NNS	B-NP
'  	'  	 POS	O
randomization  	randomization  	 JJ	B-NP
assignments  	assignments  	 NN	I-NP
and  	and  	 CC	O
HF  	HF  	 NNP	B-NP
outcome  	outcome  	 NN	I-NP
status 	status 	 NN	I-NP
,  	,  	 ,	O
regardless  	regardless  	 RB	O
of  	of  	 IN	O
subsequent  	subsequent  	 JJ	O
medication  	medication  	 NN	B-NP
adherence 	adherence 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
Kaplan-Meier  	Kaplan-Meier  	 JJ	B-NP
method  	method  	 NN	I-NP
was  	was  	 VBD	O
utilized  	utilized  	 VBN	O
in  	in  	 IN	O
calculating  	calculating  	 VBG	O
cumulative  	cumulative  	 JJ	B-NP
event  	event  	 NN	I-NP
rates 	rates 	 NNS	I-NP
.  	.  	 .	O
Descriptive  	Descriptive  	 JJ	B-NP
statistics  	statistics  	 NNS	I-NP
by  	by  	 IN	O
treatment  	treatment  	 NN	B-NP
groups  	groups  	 NNS	I-NP
were  	were  	 VBD	O
presented  	presented  	 VBN	O
for  	for  	 IN	O
baseline  	baseline  	 NN	B-NP
characteristics 	characteristics 	 NNS	I-NP
,  	,  	 ,	O
HF  	HF  	 NNP	B-NP
ascertainment 	ascertainment 	 NN	I-NP
,  	,  	 ,	O
ejection  	ejection  	 JJ	B-NP
fractions  	fractions  	 NNS	I-NP
and  	and  	 CC	O
use  	use  	 NN	O
of  	of  	 IN	O
HF  	HF  	 NNP	B-NP
medications 	medications 	 NN	I-NP
.  	.  	 .	O
Comparability  	Comparability  	 NNP	B-NP
of  	of  	 IN	I-NP
baseline  	baseline  	 NN	I-NP
characteristics  	characteristics  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
and  	and  	 CC	O
HF  	HF  	 NNP	B-NP
outcome  	outcome  	 NN	I-NP
groups  	groups  	 NNS	I-NP
was  	was  	 VBD	O
ascertained  	ascertained  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
χ  	χ  	 JJ	O
2test  	2test  	 NN	O
for  	for  	 IN	O
categorical  	categorical  	 JJ	B-NP
variables  	variables  	 NNS	I-NP
and  	and  	 CC	O
standard  	standard  	 JJ	O
normal  	normal  	 JJ	O
( 	( 	 -LRB-	O
z 	z 	 LS	O
)  	)  	 -RRB-	O
test  	test  	 NN	O
for  	for  	 IN	O
continuous  	continuous  	 JJ	B-NP
variables 	variables 	 NNS	I-NP
.  	.  	 .	O
Results  	Results  	 NNP	O
Heart  	Heart  	 NNP	B-NP
Failure  	Failure  	 NNP	I-NP
Diagnostic  	Diagnostic  	 NNP	I-NP
Criteria  	Criteria  	 NNP	I-NP
The  	The  	 DT	O
blinded  	blinded  	 JJ	O
review  	review  	 NN	O
by  	by  	 IN	O
the  	the  	 DT	O
Endpoints  	Endpoints  	 NNP	B-NP
Subcommittee  	Subcommittee  	 NNP	O
of  	of  	 IN	O
50  	50  	 CD	O
fatal  	fatal  	 NNS	O
or  	or  	 CC	O
hospitalized  	hospitalized  	 VBN	B-NP
HF  	HF  	 NNP	I-NP
events  	events  	 NNS	I-NP
from  	from  	 IN	O
the  	the  	 DT	O
4  	4  	 CD	O
drug  	drug  	 NN	B-NP
groups  	groups  	 NNS	I-NP
determined  	determined  	 VBD	O
11  	11  	 CD	O
( 	( 	 -LRB-	O
22 	22 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
to  	to  	 TO	O
have  	have  	 VB	O
incomplete  	incomplete  	 JJ	O
data  	data  	 NNS	O
for  	for  	 IN	O
a  	a  	 DT	O
definitive  	definitive  	 JJ	O
review 	review 	 NN	O
.  	.  	 .	O
Of  	Of  	 IN	O
the  	the  	 DT	O
remaining  	remaining  	 JJ	O
39 	39 	 CD	O
,  	,  	 ,	O
33  	33  	 CD	O
( 	( 	 -LRB-	O
85 	85 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
were  	were  	 VBD	O
confirmed  	confirmed  	 VBN	O
to  	to  	 TO	O
have  	have  	 VB	O
HF  	HF  	 NNP	B-NP
by  	by  	 IN	O
one  	one  	 CD	O
or  	or  	 CC	O
both  	both  	 DT	O
reviewers 	reviewers 	 NN	O
.  	.  	 .	O
For  	For  	 IN	O
both  	both  	 PDT	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 NN	B-NP
and  	and  	 CC	O
doxazosin  	doxazosin  	 JJ	B-NP
groups 	groups 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
diagnosis  	diagnosis  	 NN	O
of  	of  	 IN	O
HF  	HF  	 NNP	B-NP
was  	was  	 VBD	O
confirmed  	confirmed  	 VBN	O
in  	in  	 IN	O
90 	90 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
18 	18 	 CD	O
/ 	/ 	 CD	O
20 	20 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Baseline  	Baseline  	 NNP	B-NP
Characteristics  	Characteristics  	 NNP	I-NP
Baseline  	Baseline  	 NNP	I-NP
characteristics  	characteristics  	 NNS	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 NN	B-NP
and  	and  	 CC	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
groups 	groups 	 NNS	I-NP
,  	,  	 ,	O
stratified  	stratified  	 VBG	O
for  	for  	 IN	O
HF  	HF  	 NNP	B-NP
status 	status 	 NN	I-NP
,  	,  	 ,	O
are  	are  	 VBP	O
described  	described  	 VBN	O
in  	in  	 IN	O
Table  	Table  	 NNP	O
1 	1 	 CD	O
.  	.  	 .	O
Baseline  	Baseline  	 JJ	B-NP
characteristics  	characteristics  	 NNS	I-NP
of  	of  	 IN	I-NP
doxazosin  	doxazosin  	 NN	I-NP
and  	and  	 CC	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
with  	with  	 IN	O
subsequent  	subsequent  	 JJ	O
hospitalized  	hospitalized  	 NN	O
or  	or  	 CC	O
fatal  	fatal  	 JJ	B-NP
HF  	HF  	 NNP	I-NP
were  	were  	 VBD	O
compared 	compared 	 VBN	O
.  	.  	 .	O
Doxazosin  	Doxazosin  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
with  	with  	 IN	O
hospitalized  	hospitalized  	 NN	O
or  	or  	 CC	O
fatal  	fatal  	 JJ	B-NP
HF  	HF  	 NNP	I-NP
had  	had  	 VBD	O
a  	a  	 DT	O
higher  	higher  	 JJR	O
baseline  	baseline  	 NN	B-NP
SBP  	SBP  	 NN	I-NP
than  	than  	 IN	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
( 	( 	 -LRB-	O
150.1  	150.1  	 FW	O
vs.  	vs.  	 FW	O
147.8  	147.8  	 FW	O
mm  	mm  	 FW	B-NP
Hg  	Hg  	 NNP	I-NP
at  	at  	 IN	O
the  	the  	 DT	O
randomization  	randomization  	 JJ	B-NP
visit 	visit 	 NN	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
More  	More  	 RBR	O
doxazosin  	doxazosin  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
had  	had  	 VBD	O
LVH  	LVH  	 NNP	B-NP
by  	by  	 IN	O
ECG  	ECG  	 NNP	B-NP
( 	( 	 -LRB-	O
22.3 	22.3 	 CD	O
%  	%  	 NN	O
vs.  	vs.  	 IN	O
20.5 	20.5 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
participants 	participants 	 NNS	I-NP
) 	) 	 -RRB-	O
;  	;  	 :	O
slightly  	slightly  	 RB	O
more  	more  	 JJR	O
chlorthalidone  	chlorthalidone  	 NN	B-NP
than  	than  	 IN	O
doxazosin  	doxazosin  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
had  	had  	 VBD	O
LVH  	LVH  	 NNP	B-NP
by  	by  	 IN	O
echocardiogram 	echocardiogram 	 NN	B-NP
.  	.  	 .	O
Several  	Several  	 JJ	O
eligibility  	eligibility  	 JJ	B-NP
risk  	risk  	 NN	I-NP
factors 	factors 	 NNS	I-NP
,  	,  	 ,	O
including  	including  	 VBG	O
previous  	previous  	 JJ	O
MIs  	MIs  	 JJ	O
or  	or  	 CC	O
strokes 	strokes 	 NNS	O
,  	,  	 ,	O
coronary  	coronary  	 JJ	B-NP
revascularization  	revascularization  	 JJ	I-NP
procedures 	procedures 	 NNS	I-NP
,  	,  	 ,	O
other  	other  	 JJ	O
atherosclerotic  	atherosclerotic  	 JJ	B-NP
cardiovascular  	cardiovascular  	 JJ	I-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
ASCVD 	ASCVD 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
ST-T  	ST-T  	 JJ	B-NP
wave  	wave  	 NN	I-NP
changes 	changes 	 NNS	I-NP
,  	,  	 ,	O
were  	were  	 VBD	O
reported  	reported  	 VBN	O
more  	more  	 RBR	O
often  	often  	 RB	O
in  	in  	 IN	O
chlorthalidone  	chlorthalidone  	 NN	B-NP
than  	than  	 IN	O
in  	in  	 IN	O
doxazosin  	doxazosin  	 JJ	B-NP
participants 	participants 	 NNS	I-NP
,  	,  	 ,	O
though  	though  	 IN	O
the  	the  	 DT	O
differences  	differences  	 NNS	O
were  	were  	 VBD	O
not  	not  	 RB	O
significant 	significant 	 JJ	O
.  	.  	 .	O
Chlorthalidone  	Chlorthalidone  	 NNP	B-NP
and  	and  	 CC	O
doxazosin  	doxazosin  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
with  	with  	 IN	O
hospitalized  	hospitalized  	 NN	O
or  	or  	 CC	O
fatal  	fatal  	 JJ	B-NP
HF  	HF  	 NNP	I-NP
had  	had  	 VBD	O
similar  	similar  	 JJ	O
pre-trial  	pre-trial  	 JJ	B-NP
antihypertensive  	antihypertensive  	 JJ	I-NP
treatment  	treatment  	 NN	I-NP
durations 	durations 	 NN	I-NP
.  	.  	 .	O
None  	None  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
differences  	differences  	 NNS	O
was  	was  	 VBD	O
significant  	significant  	 JJ	O
at  	at  	 IN	O
P  	P  	 NNP	O
< 	< 	 SYM	O
.05 	.05 	 NNP	O
.  	.  	 .	O
Participants  	Participants  	 NNS	B-NP
with  	with  	 IN	O
HF  	HF  	 NNP	B-NP
events  	events  	 NNS	I-NP
displayed  	displayed  	 VBD	O
higher  	higher  	 JJR	O
rates  	rates  	 NNS	O
of  	of  	 IN	O
most  	most  	 RBS	O
cardiovascular  	cardiovascular  	 JJ	B-NP
risk  	risk  	 NN	I-NP
factors  	factors  	 NNS	I-NP
compared  	compared  	 VBN	O
to  	to  	 TO	O
those  	those  	 DT	O
without  	without  	 IN	O
HF  	HF  	 NNP	B-NP
events 	events 	 NNS	I-NP
.  	.  	 .	O
Approximately  	Approximately  	 RB	O
35-36 	35-36 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
chlorthalidone  	chlorthalidone  	 NN	B-NP
and  	and  	 CC	O
doxazosin  	doxazosin  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
with  	with  	 IN	O
fatal  	fatal  	 JJ	O
or  	or  	 CC	O
hospitalized  	hospitalized  	 VBN	B-NP
HF  	HF  	 NNP	I-NP
had  	had  	 VBD	O
reported  	reported  	 VBN	O
prior  	prior  	 JJ	O
MI  	MI  	 NNP	O
or  	or  	 CC	O
stroke  	stroke  	 NN	O
as  	as  	 IN	O
baseline  	baseline  	 JJ	B-NP
eligibility  	eligibility  	 JJ	I-NP
risk  	risk  	 NN	I-NP
factors 	factors 	 NNS	I-NP
,  	,  	 ,	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
22-23 	22-23 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
those  	those  	 DT	O
without  	without  	 IN	O
HF  	HF  	 NNP	B-NP
(  	(  	 -LRB-	O
P  	P  	 NNP	O
< 	< 	 SYM	O
.001 	.001 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Participants  	Participants  	 NNS	B-NP
with  	with  	 IN	O
hospitalized 	hospitalized 	 FW	B-NP
/ 	/ 	 FW	I-NP
fatal  	fatal  	 FW	I-NP
HF  	HF  	 NNP	I-NP
had  	had  	 VBD	O
significantly  	significantly  	 RB	O
higher  	higher  	 JJR	O
rates  	rates  	 NNS	O
of  	of  	 IN	O
pre-randomization  	pre-randomization  	 FW	B-NP
coronary  	coronary  	 FW	I-NP
artery  	artery  	 FW	I-NP
bypass  	bypass  	 FW	I-NP
grafts  	grafts  	 FW	I-NP
( 	( 	 -LRB-	O
CABGs 	CABGs 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
coronary  	coronary  	 JJ	B-NP
angioplasties  	angioplasties  	 NNS	I-NP
( 	( 	 -LRB-	O
19-23 	19-23 	 NNP	O
%  	%  	 NN	O
of  	of  	 IN	O
those  	those  	 DT	O
with  	with  	 IN	O
HF  	HF  	 NNP	B-NP
vs.  	vs.  	 CC	O
13 	13 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
those  	those  	 DT	O
without 	without 	 NN	O
;  	;  	 :	O
P  	P  	 NNP	O
< 	< 	 SYM	O
.001 	.001 	 NNP	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
other  	other  	 JJ	O
atherosclerotic  	atherosclerotic  	 JJ	B-NP
cardiovascular  	cardiovascular  	 JJ	I-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
ASCVD 	ASCVD 	 NNP	B-NP
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
29-33 	29-33 	 NNP	O
%  	%  	 NN	O
of  	of  	 IN	O
those  	those  	 DT	O
with  	with  	 IN	O
HF  	HF  	 NNP	O
vs.  	vs.  	 FW	O
23-25 	23-25 	 FW	O
%  	%  	 NN	O
of  	of  	 IN	O
those  	those  	 DT	O
without 	without 	 NN	O
;  	;  	 :	O
P  	P  	 NNP	O
< 	< 	 SYM	O
.001 	.001 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Diabetes  	Diabetes  	 NN	O
as  	as  	 IN	O
a  	a  	 DT	O
baseline  	baseline  	 NN	O
risk  	risk  	 NN	O
factor  	factor  	 NN	O
occurred  	occurred  	 VBD	O
more  	more  	 RBR	O
frequently  	frequently  	 RB	O
in  	in  	 IN	O
those  	those  	 DT	O
with  	with  	 IN	O
HF 	HF 	 NNP	O
:  	:  	 :	O
47-48 	47-48 	 CD	O
%  	%  	 NN	O
in  	in  	 IN	O
those  	those  	 DT	O
with  	with  	 IN	O
HF 	HF 	 NNP	O
,  	,  	 ,	O
35-36 	35-36 	 CD	O
%  	%  	 NN	O
in  	in  	 IN	O
those  	those  	 DT	O
without  	without  	 IN	O
(  	(  	 -LRB-	O
P  	P  	 NNP	O
< 	< 	 SYM	O
.001 	.001 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Left  	Left  	 VBN	B-NP
ventricular  	ventricular  	 JJ	I-NP
hypertrophy  	hypertrophy  	 NNS	I-NP
( 	( 	 -LRB-	O
LVH 	LVH 	 NNP	B-NP
)  	)  	 -RRB-	O
by  	by  	 IN	O
ECG  	ECG  	 NNP	O
was  	was  	 VBD	O
a  	a  	 DT	O
risk  	risk  	 NN	O
factor  	factor  	 NN	O
in  	in  	 IN	O
21-22 	21-22 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
those  	those  	 DT	O
who  	who  	 WP	O
later  	later  	 RB	O
developed  	developed  	 VBN	O
HF 	HF 	 NNP	O
,  	,  	 ,	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
16 	16 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
those  	those  	 DT	O
in  	in  	 IN	O
each  	each  	 DT	O
group  	group  	 NN	O
who  	who  	 WP	O
did  	did  	 VBD	O
not  	not  	 RB	O
develop  	develop  	 VB	O
HF  	HF  	 NNP	O
(  	(  	 -LRB-	O
P  	P  	 NNP	O
< 	< 	 SYM	O
.001 	.001 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Baseline  	Baseline  	 JJ	B-NP
pulse  	pulse  	 NN	I-NP
pressure  	pressure  	 NN	I-NP
( 	( 	 -LRB-	O
PP 	PP 	 NNP	B-NP
)  	)  	 -RRB-	O
showed  	showed  	 VBD	O
some  	some  	 DT	O
variation  	variation  	 NN	O
between  	between  	 IN	O
participants  	participants  	 NNS	B-NP
who  	who  	 WP	O
did  	did  	 VBD	O
and  	and  	 CC	O
did  	did  	 VBD	O
not  	not  	 RB	O
develop  	develop  	 VB	O
HF 	HF 	 NNP	B-NP
.  	.  	 .	O
For  	For  	 IN	O
participants  	participants  	 NNS	B-NP
with  	with  	 IN	O
subsequent  	subsequent  	 JJ	O
hospitalization  	hospitalization  	 NN	B-NP
or  	or  	 CC	O
death  	death  	 NN	O
from  	from  	 IN	O
HF 	HF 	 NNP	B-NP
,  	,  	 ,	O
PP  	PP  	 NNP	B-NP
was  	was  	 VBD	O
67  	67  	 CD	O
and  	and  	 CC	O
68  	68  	 CD	O
mm  	mm  	 CD	B-NP
Hg  	Hg  	 NNS	I-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
chlorthalidone  	chlorthalidone  	 NN	I-NP
and  	and  	 CC	O
doxazosin  	doxazosin  	 JJ	B-NP
groups 	groups 	 NNS	I-NP
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
Treated 	Treated 	 NNP	O
,  	,  	 ,	O
non-hospitalized  	non-hospitalized  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
showed  	showed  	 VBD	O
a  	a  	 DT	O
lower  	lower  	 JJR	O
mean  	mean  	 JJ	B-NP
baseline  	baseline  	 NN	I-NP
PP  	PP  	 NN	I-NP
of  	of  	 IN	O
65  	65  	 CD	O
( 	( 	 -LRB-	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
group 	group 	 NN	I-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
64  	64  	 CD	O
mm  	mm  	 JJ	B-NP
Hg  	Hg  	 NNP	I-NP
( 	( 	 -LRB-	O
doxazosin  	doxazosin  	 JJ	B-NP
group 	group 	 NN	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
an  	an  	 DT	O
even  	even  	 RB	O
lower  	lower  	 RBR	O
mean  	mean  	 JJ	B-NP
PP  	PP  	 NN	I-NP
in  	in  	 IN	O
those  	those  	 DT	O
without  	without  	 IN	O
HF  	HF  	 NNP	B-NP
( 	( 	 -LRB-	O
62  	62  	 CD	O
mm  	mm  	 CD	B-NP
Hg  	Hg  	 NNS	I-NP
in  	in  	 IN	O
each  	each  	 DT	O
group 	group 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Medical  	Medical  	 NNP	O
Management  	Management  	 NNP	O
Table  	Table  	 NNP	O
2presents  	2presents  	 NNP	O
post-event  	post-event  	 JJ	O
pharmacologic  	pharmacologic  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
of  	of  	 IN	I-NP
participants  	participants  	 NNS	I-NP
with  	with  	 IN	O
HF  	HF  	 NNP	B-NP
and  	and  	 CC	O
antihypertensive  	antihypertensive  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
of  	of  	 IN	I-NP
participants  	participants  	 NNS	I-NP
without  	without  	 IN	O
HF 	HF 	 NNP	B-NP
.  	.  	 .	O
Following  	Following  	 VBG	O
hospitalization  	hospitalization  	 NN	B-NP
for  	for  	 IN	I-NP
HF 	HF 	 NNP	I-NP
,  	,  	 ,	O
36 	36 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
83 	83 	 CD	O
/ 	/ 	 CD	O
232 	232 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
and  	and  	 CC	O
45 	45 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
126 	126 	 CD	O
/ 	/ 	 CD	O
281 	281 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
doxazosin  	doxazosin  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
remained  	remained  	 VBD	O
on  	on  	 IN	O
their  	their  	 PRP$	O
blinded  	blinded  	 JJ	O
medications 	medications 	 NN	O
.  	.  	 .	O
Percentages  	Percentages  	 NNS	O
of  	of  	 IN	O
participants  	participants  	 NNS	B-NP
on  	on  	 IN	O
open-label  	open-label  	 JJ	B-NP
diuretics  	diuretics  	 NN	I-NP
and  	and  	 CC	O
ACE-inhibitors  	ACE-inhibitors  	 NNP	B-NP
were  	were  	 VBD	O
similar  	similar  	 JJ	O
following  	following  	 VBG	O
the  	the  	 DT	O
event 	event 	 NN	O
:  	:  	 :	O
58 	58 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
135 	135 	 CD	O
/ 	/ 	 CD	O
232 	232 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
and  	and  	 CC	O
64 	64 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
180 	180 	 CD	O
/ 	/ 	 CD	O
281 	281 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
doxazosin  	doxazosin  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
were  	were  	 VBD	O
prescribed  	prescribed  	 VBN	B-NP
open-label  	open-label  	 JJ	I-NP
diuretics 	diuretics 	 NN	I-NP
;  	;  	 :	O
39 	39 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
90 	90 	 CD	O
/ 	/ 	 CD	O
232 	232 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
and  	and  	 CC	O
41 	41 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
114 	114 	 CD	O
/ 	/ 	 CD	O
281 	281 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
doxazosin  	doxazosin  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
were  	were  	 VBD	O
prescribed  	prescribed  	 VBN	B-NP
open-label  	open-label  	 JJ	I-NP
ACE-inhibitors 	ACE-inhibitors 	 NN	I-NP
.  	.  	 .	O
Beta-blockers  	Beta-blockers  	 NNP	B-NP
were  	were  	 VBD	O
prescribed  	prescribed  	 VBN	O
for  	for  	 IN	O
14 	14 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
each  	each  	 DT	O
group  	group  	 NN	O
following  	following  	 VBG	O
the  	the  	 DT	O
event 	event 	 NN	O
,  	,  	 ,	O
which  	which  	 WDT	O
was  	was  	 VBD	O
actually  	actually  	 RB	O
somewhat  	somewhat  	 RB	O
less  	less  	 JJR	O
than  	than  	 IN	O
for  	for  	 IN	O
participants  	participants  	 NNS	B-NP
who  	who  	 WP	O
did  	did  	 VBD	O
not  	not  	 RB	O
develop  	develop  	 VB	O
HF 	HF 	 NNP	B-NP
.  	.  	 .	O
Three-quarters  	Three-quarters  	 NNS	O
of  	of  	 IN	O
hospitalized  	hospitalized  	 JJ	O
HF  	HF  	 NN	B-NP
participants  	participants  	 NNS	I-NP
in  	in  	 IN	O
each  	each  	 DT	O
group  	group  	 NN	O
( 	( 	 -LRB-	O
169 	169 	 CD	O
/ 	/ 	 CD	O
232  	232  	 CD	O
in  	in  	 IN	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
group 	group 	 NN	I-NP
,  	,  	 ,	O
210 	210 	 CD	O
/ 	/ 	 CD	O
281  	281  	 CD	O
in  	in  	 IN	O
doxazosin  	doxazosin  	 JJ	B-NP
group 	group 	 NN	I-NP
)  	)  	 -RRB-	O
received  	received  	 VBD	O
at  	at  	 IN	O
least  	least  	 JJS	O
one  	one  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
three  	three  	 CD	O
medications  	medications  	 NNS	O
( 	( 	 -LRB-	O
diuretic 	diuretic 	 UH	B-NP
,  	,  	 ,	O
ACE-inhibitor 	ACE-inhibitor 	 NNP	B-NP
,  	,  	 ,	O
or  	or  	 CC	O
beta-blocker 	beta-blocker 	 NN	B-NP
)  	)  	 -RRB-	O
post-hospitalization 	post-hospitalization 	 JJ	B-NP
.  	.  	 .	O
Among  	Among  	 IN	O
participants  	participants  	 NNS	B-NP
treated  	treated  	 VBN	O
but  	but  	 CC	O
not  	not  	 RB	O
hospitalized  	hospitalized  	 VBN	O
for  	for  	 IN	O
HF 	HF 	 NNP	B-NP
,  	,  	 ,	O
58 	58 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
54 	54 	 CD	O
/ 	/ 	 CD	O
93 	93 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
group  	group  	 NN	I-NP
and  	and  	 CC	O
64 	64 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
93 	93 	 CD	O
/ 	/ 	 CD	O
145 	145 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
group  	group  	 NN	I-NP
remained  	remained  	 VBD	O
on  	on  	 IN	O
their  	their  	 PRP$	O
blinded  	blinded  	 JJ	O
medication 	medication 	 NN	O
.  	.  	 .	O
Over  	Over  	 IN	O
60 	60 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
participants  	participants  	 NNS	B-NP
in  	in  	 IN	O
each  	each  	 DT	O
group  	group  	 NN	O
were  	were  	 VBD	O
prescribed  	prescribed  	 VBN	B-NP
open-label  	open-label  	 JJ	I-NP
diuretics  	diuretics  	 NN	I-NP
and  	and  	 CC	O
over  	over  	 IN	O
30 	30 	 CD	O
%  	%  	 NN	O
received  	received  	 VBD	B-NP
ACE-inhibitors 	ACE-inhibitors 	 JJ	I-NP
.  	.  	 .	O
Open-label  	Open-label  	 JJ	B-NP
beta-blocker  	beta-blocker  	 NN	I-NP
use  	use  	 NN	I-NP
post-event  	post-event  	 NN	I-NP
occurred  	occurred  	 VBD	O
in  	in  	 IN	O
19 	19 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
18 	18 	 CD	O
/ 	/ 	 CD	O
93 	93 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
group  	group  	 NN	I-NP
and  	and  	 CC	O
22 	22 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
32 	32 	 CD	O
/ 	/ 	 CD	O
145 	145 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
group 	group 	 NN	I-NP
,  	,  	 ,	O
approximately  	approximately  	 RB	O
the  	the  	 DT	O
same  	same  	 JJ	O
frequency  	frequency  	 NN	O
as  	as  	 IN	O
in  	in  	 IN	O
participants  	participants  	 NNS	B-NP
without  	without  	 IN	O
HF 	HF 	 NNP	B-NP
.  	.  	 .	O
In  	In  	 IN	O
both  	both  	 DT	O
treatment  	treatment  	 NN	B-NP
groups 	groups 	 NNS	I-NP
,  	,  	 ,	O
a  	a  	 DT	O
diuretic 	diuretic 	 NN	B-NP
,  	,  	 ,	O
ACE-inhibitor  	ACE-inhibitor  	 JJ	B-NP
or  	or  	 CC	O
beta-blocker  	beta-blocker  	 NN	B-NP
was  	was  	 VBD	O
prescribed  	prescribed  	 VBN	O
for  	for  	 IN	O
over  	over  	 IN	O
75 	75 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
participants  	participants  	 NNS	B-NP
( 	( 	 -LRB-	O
72 	72 	 CD	O
/ 	/ 	 CD	O
93  	93  	 CD	O
in  	in  	 IN	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
group 	group 	 NN	I-NP
,  	,  	 ,	O
119 	119 	 CD	O
/ 	/ 	 CD	O
145  	145  	 CD	O
in  	in  	 IN	O
doxazosin  	doxazosin  	 JJ	B-NP
group 	group 	 NN	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Ejection  	Ejection  	 NNP	O
Fraction  	Fraction  	 NNP	O
Review  	Review  	 NNP	O
Table  	Table  	 NNP	O
3displays  	3displays  	 CD	O
the  	the  	 DT	O
ejection  	ejection  	 JJ	B-NP
fraction  	fraction  	 NN	I-NP
data 	data 	 NNS	I-NP
.  	.  	 .	O
About  	About  	 IN	O
half  	half  	 NN	O
( 	( 	 -LRB-	O
178 	178 	 CD	O
/ 	/ 	 CD	O
361 	361 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
reviewed  	reviewed  	 FW	B-NP
discharge  	discharge  	 FW	I-NP
summaries  	summaries  	 FW	I-NP
mentioned  	mentioned  	 FW	I-NP
ejection  	ejection  	 FW	I-NP
fractions  	fractions  	 FW	I-NP
measured  	measured  	 VBN	O
during  	during  	 IN	O
hospitalization 	hospitalization 	 NN	B-NP
,  	,  	 ,	O
two-thirds  	two-thirds  	 NNS	B-NP
( 	( 	 -LRB-	O
116 	116 	 CD	O
/ 	/ 	 CD	O
169 	169 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
which  	which  	 WDT	O
had  	had  	 VBD	O
quantitative  	quantitative  	 JJ	B-NP
measurements  	measurements  	 NNS	I-NP
reported  	reported  	 VBD	O
in  	in  	 IN	O
the  	the  	 DT	O
discharge  	discharge  	 NN	B-NP
summaries  	summaries  	 NNS	I-NP
( 	( 	 -LRB-	O
data  	data  	 NNS	O
not  	not  	 RB	O
given 	given 	 VBN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Considering  	Considering  	 VBG	O
only  	only  	 RB	O
the  	the  	 DT	O
earliest  	earliest  	 JJS	O
ejection  	ejection  	 JJ	B-NP
fraction  	fraction  	 NN	I-NP
information  	information  	 NN	I-NP
ascertained  	ascertained  	 NN	I-NP
for  	for  	 IN	O
each  	each  	 DT	O
HF  	HF  	 NNP	B-NP
participant 	participant 	 NN	I-NP
,  	,  	 ,	O
63 	63 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
29 	29 	 CD	O
/ 	/ 	 CD	O
46 	46 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 NN	B-NP
and  	and  	 CC	O
70 	70 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
41 	41 	 CD	O
/ 	/ 	 CD	O
59 	59 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
had  	had  	 VBD	O
ejection  	ejection  	 JJ	B-NP
fractions  	fractions  	 NNS	I-NP
at  	at  	 IN	O
or  	or  	 CC	O
below  	below  	 IN	O
40 	40 	 CD	O
% 	% 	 NN	O
.  	.  	 .	O
Just  	Just  	 RB	O
under  	under  	 IN	O
half  	half  	 NN	O
( 	( 	 -LRB-	O
27 	27 	 CD	O
/ 	/ 	 CD	O
59 	59 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
the  	the  	 DT	O
ejection  	ejection  	 JJ	B-NP
fractions  	fractions  	 NNS	I-NP
reported  	reported  	 VBD	O
in  	in  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
group  	group  	 NN	I-NP
were  	were  	 VBD	O
at  	at  	 IN	O
or  	or  	 CC	O
below  	below  	 IN	O
30 	30 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
one  	one  	 CD	O
third  	third  	 JJ	O
( 	( 	 -LRB-	O
15 	15 	 CD	O
/ 	/ 	 CD	O
46 	46 	 CD	O
)  	)  	 -RRB-	O
in  	in  	 IN	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
group 	group 	 NN	I-NP
.  	.  	 .	O
Two-thirds  	Two-thirds  	 NNS	B-NP
of  	of  	 IN	I-NP
ejection  	ejection  	 JJ	I-NP
fractions  	fractions  	 NNS	I-NP
were  	were  	 VBD	O
obtained  	obtained  	 VBN	O
by  	by  	 IN	O
echocardiograms 	echocardiograms 	 NN	B-NP
,  	,  	 ,	O
though  	though  	 IN	O
catheterizations  	catheterizations  	 NN	B-NP
accounted  	accounted  	 VBD	O
for  	for  	 IN	O
a  	a  	 DT	O
larger  	larger  	 JJR	O
percentage  	percentage  	 NN	O
of  	of  	 IN	O
results  	results  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
group  	group  	 NN	I-NP
than  	than  	 IN	O
in  	in  	 IN	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
36 	36 	 CD	O
%  	%  	 NN	O
vs.  	vs.  	 IN	O
24 	24 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Causes  	Causes  	 NNS	O
of  	of  	 IN	O
Death  	Death  	 NNP	O
and  	and  	 CC	O
2-Year  	2-Year  	 NNP	O
Case-Fatality  	Case-Fatality  	 NNP	O
Causes  	Causes  	 NNP	O
of  	of  	 IN	O
death  	death  	 NN	O
of  	of  	 IN	O
participants  	participants  	 NNS	B-NP
with  	with  	 IN	O
previous  	previous  	 JJ	O
HF  	HF  	 NNP	B-NP
hospitalization  	hospitalization  	 NN	I-NP
were  	were  	 VBD	O
distributed  	distributed  	 VBN	O
similarly  	similarly  	 RB	O
in  	in  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
groups 	groups 	 NNS	O
,  	,  	 ,	O
with  	with  	 IN	O
slight  	slight  	 JJ	O
variations 	variations 	 NNS	O
.  	.  	 .	O
HF  	HF  	 NNP	B-NP
accounted  	accounted  	 VBD	O
for  	for  	 IN	O
21.2 	21.2 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
11 	11 	 CD	O
/ 	/ 	 CD	O
52 	52 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
the  	the  	 DT	O
deaths  	deaths  	 NNS	O
among  	among  	 IN	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
and  	and  	 CC	O
17.1 	17.1 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
12 	12 	 CD	O
/ 	/ 	 CD	O
70 	70 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
the  	the  	 DT	O
deaths  	deaths  	 NNS	O
among  	among  	 IN	O
doxazosin  	doxazosin  	 JJ	B-NP
participants 	participants 	 NNS	I-NP
.  	.  	 .	O
Over  	Over  	 IN	O
half  	half  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
deaths  	deaths  	 NNS	O
in  	in  	 IN	O
each  	each  	 DT	O
group  	group  	 NN	O
( 	( 	 -LRB-	O
29 	29 	 CD	O
/ 	/ 	 CD	O
52  	52  	 CD	O
in  	in  	 IN	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
group 	group 	 NN	I-NP
;  	;  	 :	O
43 	43 	 CD	O
/ 	/ 	 CD	O
70  	70  	 CD	O
in  	in  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
group 	group 	 NN	I-NP
)  	)  	 -RRB-	O
were  	were  	 VBD	O
due  	due  	 JJ	O
to  	to  	 TO	O
cardiovascular  	cardiovascular  	 JJ	B-NP
events 	events 	 NNS	I-NP
.  	.  	 .	O
Fifteen  	Fifteen  	 JJ	O
percent  	percent  	 NN	O
( 	( 	 -LRB-	O
8 	8 	 CD	O
/ 	/ 	 CD	O
52 	52 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
deaths  	deaths  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
group  	group  	 NN	I-NP
were  	were  	 VBD	O
attributed  	attributed  	 VBN	O
to  	to  	 TO	O
cancer 	cancer 	 NN	O
,  	,  	 ,	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
9 	9 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
6 	6 	 CD	O
/ 	/ 	 CD	O
70 	70 	 CD	O
)  	)  	 -RRB-	O
in  	in  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
Table  	Table  	 NNP	O
4 	4 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Case-fatality  	Case-fatality  	 JJ	B-NP
for  	for  	 IN	I-NP
participants  	participants  	 NNS	I-NP
with  	with  	 IN	O
hospitalized  	hospitalized  	 JJ	O
HF  	HF  	 NN	B-NP
events  	events  	 NNS	I-NP
showed  	showed  	 VBD	O
no  	no  	 DT	O
significant  	significant  	 JJ	O
differences  	differences  	 NNS	O
( 	( 	 -LRB-	O
RR  	RR  	 NNP	B-NP
0.96 	0.96 	 NNP	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
CI 	CI 	 NNP	O
,  	,  	 ,	O
0.67-1.38 	0.67-1.38 	 NNP	O
,  	,  	 ,	O
P  	P  	 NN	O
=  	=  	 SYM	O
0.83 	0.83 	 CD	O
)  	)  	 -RRB-	O
between  	between  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
treatment  	treatment  	 NN	B-NP
groups  	groups  	 NNS	I-NP
( 	( 	 -LRB-	O
Figure  	Figure  	 NNP	O
1 	1 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Among  	Among  	 IN	O
participants  	participants  	 NNS	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
group  	group  	 NN	I-NP
who  	who  	 WP	O
had  	had  	 VBD	O
been  	been  	 VBN	O
previously  	previously  	 RB	O
hospitalized  	hospitalized  	 VBN	O
for  	for  	 IN	O
HF 	HF 	 NNP	B-NP
,  	,  	 ,	O
22.1 	22.1 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
70 	70 	 CD	O
/ 	/ 	 CD	O
317 	317 	 CD	O
)  	)  	 -RRB-	O
subsequently  	subsequently  	 RB	O
died 	died 	 VBD	O
,  	,  	 ,	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
18.6 	18.6 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
52 	52 	 CD	O
/ 	/ 	 CD	O
280 	280 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
those  	those  	 DT	O
in  	in  	 IN	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
Table  	Table  	 NNP	O
4 	4 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
As  	As  	 RB	O
previously  	previously  	 RB	O
reported 	reported 	 VBN	O
,  	,  	 ,	O
all-cause  	all-cause  	 JJ	O
mortality  	mortality  	 NN	O
did  	did  	 VBD	O
not  	not  	 RB	O
significantly  	significantly  	 RB	O
differ  	differ  	 VB	O
in  	in  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
treatment  	treatment  	 NN	O
groups  	groups  	 NNS	O
( 	( 	 -LRB-	O
RR  	RR  	 NNP	O
1.03 	1.03 	 CD	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
0.90-1.15 	0.90-1.15 	 NNP	O
,  	,  	 ,	O
P  	P  	 NN	O
=  	=  	 SYM	O
0.56 	0.56 	 CD	O
)  	)  	 -RRB-	O
[  	[  	 -LRB-	O
2  	2  	 LS	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Discussion  	Discussion  	 NN	O
The  	The  	 DT	O
finding  	finding  	 NN	O
of  	of  	 IN	O
significantly  	significantly  	 RB	O
increased  	increased  	 VBN	B-NP
HF  	HF  	 NNP	I-NP
events  	events  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
group  	group  	 NN	I-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
group  	group  	 NN	I-NP
created  	created  	 VBD	O
a  	a  	 DT	O
dilemma  	dilemma  	 NN	O
for  	for  	 IN	O
ALLHAT 	ALLHAT 	 NNP	B-NP
.  	.  	 .	O
Since  	Since  	 IN	O
the  	the  	 DT	O
trial  	trial  	 NN	O
was  	was  	 VBD	O
not  	not  	 RB	O
designed  	designed  	 VBN	O
to  	to  	 TO	O
focus  	focus  	 VB	O
on  	on  	 IN	O
HF 	HF 	 NNP	B-NP
,  	,  	 ,	O
a  	a  	 DT	O
component  	component  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
secondary  	secondary  	 JJ	B-NP
endpoint 	endpoint 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
validity  	validity  	 NN	O
of  	of  	 IN	O
reported  	reported  	 VBN	B-NP
HF  	HF  	 NNP	I-NP
events  	events  	 NNS	I-NP
became  	became  	 VBD	O
an  	an  	 DT	O
issue 	issue 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
paper 	paper 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
have  	have  	 VBP	O
described  	described  	 VBN	O
several  	several  	 JJ	O
analyses  	analyses  	 NNS	O
to  	to  	 TO	O
address  	address  	 VB	O
this  	this  	 DT	O
concern 	concern 	 NN	O
.  	.  	 .	O
As  	As  	 RB	O
previously  	previously  	 RB	O
reported 	reported 	 VBN	O
,  	,  	 ,	O
lost-to-follow-up  	lost-to-follow-up  	 JJ	B-NP
and  	and  	 CC	O
event  	event  	 NN	B-NP
documentation  	documentation  	 NN	I-NP
were  	were  	 VBD	O
similar  	similar  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
treatment  	treatment  	 NN	B-NP
groups  	groups  	 NNS	I-NP
[  	[  	 -LRB-	O
2  	2  	 LS	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Steps  	Steps  	 NNS	O
employed  	employed  	 VBN	O
to  	to  	 TO	O
validate  	validate  	 VB	O
the  	the  	 DT	O
HF  	HF  	 NNP	B-NP
outcome  	outcome  	 NN	I-NP
in  	in  	 IN	O
these  	these  	 DT	O
treatment  	treatment  	 NN	B-NP
groups  	groups  	 NNS	I-NP
confirmed  	confirmed  	 VBD	O
the  	the  	 DT	O
consistency  	consistency  	 NN	O
of  	of  	 IN	O
HF  	HF  	 NNP	B-NP
event  	event  	 NN	I-NP
reporting 	reporting 	 NN	I-NP
.  	.  	 .	O
Participants  	Participants  	 NNS	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
drug  	drug  	 NN	B-NP
groups  	groups  	 NNS	I-NP
had  	had  	 VBD	O
similar  	similar  	 JJ	O
baseline  	baseline  	 NN	B-NP
characteristics  	characteristics  	 NNS	I-NP
when  	when  	 WRB	O
stratified  	stratified  	 NNS	O
by  	by  	 IN	O
HF  	HF  	 NNP	B-NP
status 	status 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
differences  	differences  	 NNS	O
in  	in  	 IN	O
eligibility  	eligibility  	 JJ	B-NP
risk  	risk  	 NN	I-NP
factors  	factors  	 NNS	I-NP
between  	between  	 IN	O
those  	those  	 DT	O
participants  	participants  	 NNS	B-NP
with  	with  	 IN	O
HF  	HF  	 NNP	B-NP
and  	and  	 CC	O
those  	those  	 DT	O
without  	without  	 NN	O
is  	is  	 VBZ	O
not  	not  	 RB	O
surprising 	surprising 	 JJ	O
:  	:  	 :	O
larger  	larger  	 JJR	O
percentages  	percentages  	 NNS	O
of  	of  	 IN	O
those  	those  	 DT	O
with  	with  	 IN	O
HF  	HF  	 NNP	B-NP
had  	had  	 VBD	O
a  	a  	 DT	O
history  	history  	 NN	O
of  	of  	 IN	O
MI 	MI 	 NNP	O
,  	,  	 ,	O
stroke 	stroke 	 NN	O
,  	,  	 ,	O
CABG 	CABG 	 NNP	B-NP
,  	,  	 ,	O
angioplasty 	angioplasty 	 NN	O
,  	,  	 ,	O
other  	other  	 JJ	O
atherosclerotic  	atherosclerotic  	 JJ	B-NP
cardiovascular  	cardiovascular  	 JJ	I-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
ASCVD 	ASCVD 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
diabetes 	diabetes 	 NN	O
,  	,  	 ,	O
low  	low  	 JJ	O
HDL  	HDL  	 NN	B-NP
levels  	levels  	 NNS	I-NP
and  	and  	 CC	O
ECG  	ECG  	 NNP	B-NP
abnormalities 	abnormalities 	 NN	I-NP
.  	.  	 .	O
Nonetheless 	Nonetheless 	 RB	O
,  	,  	 ,	O
these  	these  	 DT	O
eligibility  	eligibility  	 JJ	B-NP
factors  	factors  	 NNS	I-NP
were  	were  	 VBD	O
not  	not  	 RB	O
substantially  	substantially  	 RB	O
different  	different  	 JJ	O
between  	between  	 IN	O
chlorthalidone  	chlorthalidone  	 NN	B-NP
and  	and  	 CC	O
doxazosin  	doxazosin  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
with  	with  	 IN	O
HF 	HF 	 NNP	B-NP
.  	.  	 .	O
Post-diagnosis  	Post-diagnosis  	 JJ	B-NP
pharmacologic  	pharmacologic  	 JJ	I-NP
management  	management  	 NN	I-NP
of  	of  	 IN	O
patients  	patients  	 NNS	O
is  	is  	 VBZ	O
one  	one  	 CD	O
measure  	measure  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
strength  	strength  	 NN	O
of  	of  	 IN	O
physicians 	physicians 	 NNS	O
'  	'  	 POS	O
confidence  	confidence  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
HF  	HF  	 NNP	B-NP
diagnoses 	diagnoses 	 NN	I-NP
.  	.  	 .	O
Open-label  	Open-label  	 JJ	B-NP
diuretics 	diuretics 	 NN	I-NP
,  	,  	 ,	O
ACE-inhibitors  	ACE-inhibitors  	 JJ	B-NP
and  	and  	 CC	O
beta-blockers 	beta-blockers 	 JJ	B-NP
,  	,  	 ,	O
all  	all  	 DT	O
recognized  	recognized  	 JJ	O
treatments  	treatments  	 NNS	O
for  	for  	 IN	O
HF 	HF 	 NNP	B-NP
,  	,  	 ,	O
were  	were  	 VBD	O
prescribed  	prescribed  	 VBN	O
similarly  	similarly  	 RB	O
for  	for  	 IN	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 NN	B-NP
and  	and  	 CC	O
doxazosin  	doxazosin  	 JJ	B-NP
groups 	groups 	 NNS	I-NP
,  	,  	 ,	O
suggesting  	suggesting  	 VBG	O
similar  	similar  	 JJ	O
assessment  	assessment  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
events  	events  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
treatment  	treatment  	 NN	B-NP
groups 	groups 	 NNS	I-NP
.  	.  	 .	O
ALLHAT  	ALLHAT  	 NNP	B-NP
criteria  	criteria  	 NNS	I-NP
for  	for  	 IN	I-NP
HF  	HF  	 NNP	I-NP
were  	were  	 VBD	O
equivalently  	equivalently  	 VBN	O
met  	met  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
groups 	groups 	 NNS	O
.  	.  	 .	O
While  	While  	 IN	O
the  	the  	 DT	O
sample  	sample  	 NN	O
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
50 	50 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
hospitalized  	hospitalized  	 NN	O
or  	or  	 CC	O
fatal  	fatal  	 JJ	B-NP
HF  	HF  	 NNP	I-NP
reports  	reports  	 VBZ	O
reviewed  	reviewed  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
ALLHAT  	ALLHAT  	 NNP	B-NP
Endpoints  	Endpoints  	 NNP	I-NP
Subcommittee  	Subcommittee  	 NNP	O
was  	was  	 VBD	O
limited  	limited  	 VBN	O
in  	in  	 IN	O
number  	number  	 NN	O
and  	and  	 CC	O
in  	in  	 IN	O
adequacy  	adequacy  	 NN	B-NP
of  	of  	 IN	O
corroborating  	corroborating  	 JJ	O
documentation 	documentation 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
review  	review  	 NN	O
nonetheless  	nonetheless  	 RB	O
showed  	showed  	 VBD	B-NP
adherence  	adherence  	 VBN	I-NP
to  	to  	 TO	O
study  	study  	 VB	O
criteria  	criteria  	 NNS	O
for  	for  	 IN	O
the  	the  	 DT	O
majority  	majority  	 NN	O
( 	( 	 -LRB-	O
85 	85 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
the  	the  	 DT	O
event  	event  	 NN	B-NP
reports 	reports 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
sometimes-discrepant  	sometimes-discrepant  	 JJ	B-NP
results  	results  	 NNS	I-NP
between  	between  	 IN	O
reviewers  	reviewers  	 JJ	O
pertained  	pertained  	 NN	O
more  	more  	 RBR	O
often  	often  	 RB	O
to  	to  	 TO	O
incomplete  	incomplete  	 JJ	O
data  	data  	 NNS	O
than  	than  	 IN	O
to  	to  	 TO	O
rejection  	rejection  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
HF  	HF  	 NNP	B-NP
diagnosis 	diagnosis 	 NN	I-NP
.  	.  	 .	O
Clinical  	Clinical  	 JJ	B-NP
use  	use  	 NN	I-NP
of  	of  	 IN	O
more  	more  	 JJR	O
objective  	objective  	 NN	B-NP
measures 	measures 	 NNS	I-NP
,  	,  	 ,	O
including  	including  	 VBG	B-NP
noninvasive  	noninvasive  	 NNS	I-NP
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
invasive  	invasive  	 JJ	B-NP
tools  	tools  	 NNS	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
measurement  	measurement  	 NN	O
of  	of  	 IN	O
left  	left  	 VBN	O
ventricular  	ventricular  	 JJ	B-NP
function 	function 	 NN	I-NP
,  	,  	 ,	O
offers  	offers  	 VBZ	O
a  	a  	 DT	O
means  	means  	 NNS	O
of  	of  	 IN	O
establishing  	establishing  	 VBG	O
and  	and  	 CC	O
quantifying  	quantifying  	 JJ	O
systolic  	systolic  	 JJ	B-NP
failure  	failure  	 NN	I-NP
in  	in  	 IN	O
cases  	cases  	 NNS	O
clinically  	clinically  	 VBP	O
suggestive  	suggestive  	 VBN	O
of  	of  	 IN	O
HF  	HF  	 NNP	B-NP
[  	[  	 -LRB-	O
7  	7  	 CD	O
10  	10  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Among  	Among  	 IN	O
the  	the  	 DT	O
ejection  	ejection  	 JJ	B-NP
fractions  	fractions  	 NNS	I-NP
reported  	reported  	 VBD	O
in  	in  	 IN	O
the  	the  	 DT	O
ALLHAT  	ALLHAT  	 NNP	B-NP
events  	events  	 NNS	I-NP
that  	that  	 WDT	O
were  	were  	 VBD	O
reviewed 	reviewed 	 VBN	O
,  	,  	 ,	O
the  	the  	 DT	O
majority  	majority  	 NN	O
fell  	fell  	 VBD	O
at  	at  	 IN	O
or  	or  	 CC	O
below  	below  	 IN	O
40 	40 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
indicating  	indicating  	 VBG	O
some  	some  	 DT	O
degree  	degree  	 NN	O
of  	of  	 IN	O
systolic  	systolic  	 JJ	B-NP
dysfunction 	dysfunction 	 NN	I-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
HF  	HF  	 NNP	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
clinical  	clinical  	 JJ	B-NP
diagnosis  	diagnosis  	 NN	I-NP
that  	that  	 WDT	O
does  	does  	 VBZ	O
not  	not  	 RB	O
necessarily  	necessarily  	 RB	O
exclude  	exclude  	 VB	O
those  	those  	 DT	O
with  	with  	 IN	O
intact  	intact  	 JJ	O
left  	left  	 JJ	O
ventricular  	ventricular  	 JJ	B-NP
systolic  	systolic  	 JJ	I-NP
function  	function  	 NN	I-NP
[  	[  	 -LRB-	O
11  	11  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Hypertension  	Hypertension  	 NNP	O
is  	is  	 VBZ	O
a  	a  	 DT	O
major  	major  	 JJ	O
risk  	risk  	 NN	B-NP
factor  	factor  	 NN	I-NP
for  	for  	 IN	I-NP
diastolic  	diastolic  	 JJ	I-NP
HF 	HF 	 NNP	I-NP
;  	;  	 :	O
as  	as  	 IN	O
many  	many  	 JJ	O
as  	as  	 IN	O
25 	25 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
asymptomatic  	asymptomatic  	 JJ	B-NP
hypertensives  	hypertensives  	 NN	I-NP
with  	with  	 IN	O
left  	left  	 VBN	O
ventricular  	ventricular  	 JJ	B-NP
hypertrophy  	hypertrophy  	 NNS	I-NP
have  	have  	 VBP	O
diastolic  	diastolic  	 JJ	B-NP
dysfunction 	dysfunction 	 NN	I-NP
.  	.  	 .	O
Additionally 	Additionally 	 RB	O
,  	,  	 ,	O
90 	90 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
coronary  	coronary  	 JJ	B-NP
artery  	artery  	 NN	I-NP
disease  	disease  	 NN	I-NP
may  	may  	 MD	O
have  	have  	 VB	O
some  	some  	 DT	O
degree  	degree  	 NN	O
of  	of  	 IN	O
diastolic  	diastolic  	 JJ	B-NP
dysfunction  	dysfunction  	 NNS	I-NP
[  	[  	 -LRB-	O
12  	12  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
two-fold  	two-fold  	 JJ	B-NP
increased  	increased  	 JJ	O
relative  	relative  	 JJ	B-NP
risk  	risk  	 NN	I-NP
of  	of  	 IN	I-NP
HF  	HF  	 NNP	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
group  	group  	 NN	I-NP
compared  	compared  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
group  	group  	 NN	I-NP
changed  	changed  	 VBD	O
little  	little  	 RB	O
when  	when  	 WRB	O
confined  	confined  	 VBN	O
to  	to  	 TO	O
hospitalized  	hospitalized  	 VB	O
and  	and  	 CC	O
fatal  	fatal  	 JJ	B-NP
events 	events 	 NNS	I-NP
.  	.  	 .	O
Further 	Further 	 RB	O
,  	,  	 ,	O
HF  	HF  	 NNP	B-NP
patients  	patients  	 NNS	I-NP
in  	in  	 IN	O
both  	both  	 PDT	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 NN	B-NP
and  	and  	 CC	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
groups  	groups  	 NNS	I-NP
showed  	showed  	 VBD	O
a  	a  	 DT	O
rather  	rather  	 RB	O
high  	high  	 JJ	O
20 	20 	 CD	O
%  	%  	 NN	O
case-fatality  	case-fatality  	 JJ	B-NP
rate  	rate  	 NN	I-NP
over  	over  	 IN	O
two  	two  	 CD	O
years 	years 	 NNS	O
,  	,  	 ,	O
as  	as  	 RB	O
expected  	expected  	 VBN	O
in  	in  	 IN	O
HF  	HF  	 NNP	B-NP
patients  	patients  	 NNS	I-NP
[  	[  	 -LRB-	O
11  	11  	 CD	O
13  	13  	 CD	O
14  	14  	 CD	O
]  	]  	 -RRB-	O
,  	,  	 ,	O
further  	further  	 RB	O
supporting  	supporting  	 VBG	O
the  	the  	 DT	O
validity  	validity  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
diagnoses  	diagnoses  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
groups 	groups 	 NNS	O
.  	.  	 .	O
Among  	Among  	 IN	O
participants  	participants  	 NNS	B-NP
hospitalized  	hospitalized  	 VBN	O
for  	for  	 IN	O
HF  	HF  	 NNP	B-NP
who  	who  	 WP	O
subsequently  	subsequently  	 RB	O
died 	died 	 VBD	O
,  	,  	 ,	O
over  	over  	 IN	O
half  	half  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
deaths  	deaths  	 NNS	O
in  	in  	 IN	O
each  	each  	 DT	O
drug  	drug  	 NN	B-NP
group  	group  	 NN	I-NP
were  	were  	 VBD	O
attributed  	attributed  	 VBN	O
to  	to  	 TO	O
cardiovascular  	cardiovascular  	 JJ	B-NP
causes 	causes 	 NNS	I-NP
.  	.  	 .	O
Treatment  	Treatment  	 NN	B-NP
group  	group  	 NN	I-NP
differences  	differences  	 NNS	I-NP
in  	in  	 IN	O
mortality  	mortality  	 NN	O
attributed  	attributed  	 VBD	O
to  	to  	 TO	O
HF  	HF  	 NNP	B-NP
may  	may  	 MD	O
take  	take  	 VB	O
time  	time  	 NN	O
to  	to  	 TO	O
be  	be  	 VB	O
recognized 	recognized 	 VBN	O
.  	.  	 .	O
Patients  	Patients  	 NNS	O
with  	with  	 IN	O
HF  	HF  	 NNP	B-NP
are  	are  	 VBP	O
at  	at  	 IN	O
risk  	risk  	 NN	O
for  	for  	 IN	O
other  	other  	 JJ	O
competing  	competing  	 VBG	B-NP
causes  	causes  	 NNS	I-NP
of  	of  	 IN	O
death 	death 	 NN	O
.  	.  	 .	O
Accordingly 	Accordingly 	 RB	O
,  	,  	 ,	O
it  	it  	 PRP	O
may  	may  	 MD	O
be  	be  	 VB	O
too  	too  	 RB	O
early  	early  	 JJ	O
to  	to  	 TO	O
determine  	determine  	 VB	O
if  	if  	 IN	O
a  	a  	 DT	O
higher  	higher  	 JJR	O
rate  	rate  	 NN	O
of  	of  	 IN	O
HF  	HF  	 NNP	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
group  	group  	 NN	I-NP
translates  	translates  	 NN	O
into  	into  	 IN	O
a  	a  	 DT	O
higher  	higher  	 JJR	O
overall  	overall  	 JJ	O
mortality  	mortality  	 NN	B-NP
rate 	rate 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
20 	20 	 CD	O
%  	%  	 NN	O
2-year  	2-year  	 CD	O
case-fatality  	case-fatality  	 JJ	B-NP
rate  	rate  	 NN	I-NP
with  	with  	 IN	O
a  	a  	 DT	O
4 	4 	 CD	O
%  	%  	 NN	O
difference  	difference  	 NN	O
in  	in  	 IN	O
HF  	HF  	 NNP	B-NP
incidence  	incidence  	 NN	I-NP
rate  	rate  	 NN	I-NP
translates  	translates  	 NN	O
into  	into  	 IN	O
a  	a  	 DT	O
0.8 	0.8 	 CD	O
%  	%  	 NN	O
potential  	potential  	 JJ	B-NP
difference  	difference  	 NN	I-NP
in  	in  	 IN	O
total  	total  	 JJ	B-NP
mortality  	mortality  	 NN	I-NP
without  	without  	 IN	O
any  	any  	 DT	O
competing  	competing  	 JJ	O
causes  	causes  	 NNS	O
of  	of  	 IN	O
death 	death 	 NN	O
.  	.  	 .	O
With  	With  	 IN	O
competing  	competing  	 VBG	B-NP
causes 	causes 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
difference  	difference  	 NN	O
would  	would  	 MD	O
be  	be  	 VB	O
smaller  	smaller  	 JJR	O
and  	and  	 CC	O
difficult  	difficult  	 JJ	O
to  	to  	 TO	O
detect  	detect  	 VB	O
even  	even  	 RB	O
in  	in  	 IN	O
a  	a  	 DT	O
trial  	trial  	 NN	O
of  	of  	 IN	O
ALLHAT 	ALLHAT 	 NNP	O
's  	's  	 POS	O
size 	size 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
diagnosis  	diagnosis  	 NN	O
of  	of  	 IN	O
HF  	HF  	 NNP	B-NP
is  	is  	 VBZ	O
generally  	generally  	 RB	O
made  	made  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
basis  	basis  	 NN	O
of  	of  	 IN	O
signs  	signs  	 NNS	O
and  	and  	 CC	O
symptoms  	symptoms  	 NNS	B-NP
that  	that  	 WDT	O
may  	may  	 MD	O
overlap  	overlap  	 VB	O
with  	with  	 IN	O
those  	those  	 DT	O
of  	of  	 IN	O
other  	other  	 JJ	O
cardiovascular  	cardiovascular  	 NN	O
and  	and  	 CC	O
pulmonary  	pulmonary  	 JJ	B-NP
pathologies 	pathologies 	 NN	I-NP
.  	.  	 .	O
Moreover 	Moreover 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
picture  	picture  	 NN	I-NP
may  	may  	 MD	O
be  	be  	 VB	O
further  	further  	 RB	O
complicated  	complicated  	 VBN	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
taking  	taking  	 VBG	O
doxazosin 	doxazosin 	 NN	B-NP
,  	,  	 ,	O
side  	side  	 NN	B-NP
effects  	effects  	 NNS	I-NP
of  	of  	 IN	O
which  	which  	 WDT	O
( 	( 	 -LRB-	O
edema 	edema 	 UH	B-NP
,  	,  	 ,	O
dyspnea 	dyspnea 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
tachycardia 	tachycardia 	 CD	B-NP
)  	)  	 -RRB-	O
[  	[  	 -LRB-	O
15  	15  	 CD	O
]  	]  	 -RRB-	O
may  	may  	 MD	O
be  	be  	 VB	O
misinterpreted  	misinterpreted  	 VBN	O
as  	as  	 IN	O
manifestations  	manifestations  	 NNS	B-NP
of  	of  	 IN	I-NP
HF 	HF 	 NNP	I-NP
.  	.  	 .	O
The  	The  	 DT	O
capture  	capture  	 NN	O
of  	of  	 IN	O
events  	events  	 NNS	O
in  	in  	 IN	O
a  	a  	 DT	O
"large  	"large  	 NNP	O
and  	and  	 CC	O
simple  	simple  	 JJ	O
trial 	trial 	 NN	O
"  	"  	 ``	O
such  	such  	 JJ	O
as  	as  	 IN	O
ALLHAT  	ALLHAT  	 NNP	B-NP
has  	has  	 VBZ	O
potential  	potential  	 JJ	B-NP
limitations 	limitations 	 NNS	I-NP
.  	.  	 .	O
Built  	Built  	 VBN	O
into  	into  	 IN	O
a  	a  	 DT	O
structure  	structure  	 NN	O
composed  	composed  	 VBN	O
largely  	largely  	 RB	O
of  	of  	 IN	O
community-based  	community-based  	 JJ	O
physicians  	physicians  	 NNS	O
is  	is  	 VBZ	O
the  	the  	 DT	O
assumption  	assumption  	 NN	O
that  	that  	 IN	O
their  	their  	 PRP$	O
characterization  	characterization  	 NN	B-NP
of  	of  	 IN	I-NP
clinical  	clinical  	 JJ	I-NP
events  	events  	 NNS	I-NP
reflects  	reflects  	 VBZ	O
diagnostic  	diagnostic  	 JJ	B-NP
standards  	standards  	 NNS	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
medical  	medical  	 JJ	I-NP
community 	community 	 NN	I-NP
,  	,  	 ,	O
and 	and 	 CC	O
,  	,  	 ,	O
as  	as  	 IN	O
such 	such 	 JJ	O
,  	,  	 ,	O
meets  	meets  	 VBZ	O
study  	study  	 NN	B-NP
criteria 	criteria 	 NNS	I-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
with  	with  	 IN	O
its  	its  	 PRP$	O
large  	large  	 JJ	O
number  	number  	 NN	O
of  	of  	 IN	O
endpoints 	endpoints 	 NN	B-NP
,  	,  	 ,	O
resources  	resources  	 NNS	O
available  	available  	 JJ	O
to  	to  	 TO	O
ALLHAT  	ALLHAT  	 NNP	B-NP
precluded  	precluded  	 VBD	O
more  	more  	 JJR	O
than  	than  	 IN	O
modest  	modest  	 JJ	O
confirmatory  	confirmatory  	 JJ	B-NP
event  	event  	 NN	I-NP
documentation 	documentation 	 NN	I-NP
.  	.  	 .	O
Resources  	Resources  	 NNP	O
were  	were  	 VBD	O
allocated  	allocated  	 VBN	O
for  	for  	 IN	O
additional  	additional  	 JJ	O
documentation  	documentation  	 NN	B-NP
for  	for  	 IN	I-NP
quality  	quality  	 NN	I-NP
control  	control  	 NN	I-NP
validation  	validation  	 VBZ	O
only  	only  	 RB	O
for  	for  	 IN	O
a  	a  	 DT	O
sample  	sample  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
primary  	primary  	 JJ	B-NP
endpoint  	endpoint  	 NNS	I-NP
( 	( 	 -LRB-	O
MIs  	MIs  	 NNP	O
and  	and  	 CC	O
fatal  	fatal  	 JJ	B-NP
CHD 	CHD 	 NNP	I-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
for  	for  	 IN	O
strokes 	strokes 	 NNS	O
.  	.  	 .	O
While  	While  	 IN	O
all  	all  	 DT	O
reported  	reported  	 JJ	O
events  	events  	 NNS	O
are  	are  	 VBP	O
reviewed  	reviewed  	 VBN	O
at  	at  	 IN	O
the  	the  	 DT	O
CTC 	CTC 	 NNP	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
sometimes  	sometimes  	 RB	O
incomplete  	incomplete  	 JJ	O
supporting  	supporting  	 JJ	O
details  	details  	 NNS	O
in  	in  	 IN	O
documentation  	documentation  	 NN	B-NP
may  	may  	 MD	O
not  	not  	 RB	O
allow  	allow  	 VB	O
for  	for  	 IN	O
validation  	validation  	 NN	B-NP
of  	of  	 IN	O
all  	all  	 DT	O
events  	events  	 NNS	O
according  	according  	 VBG	O
to  	to  	 TO	O
ALLHAT  	ALLHAT  	 NNP	B-NP
criteria 	criteria 	 NNS	I-NP
.  	.  	 .	O
Some  	Some  	 DT	O
discharge  	discharge  	 NN	B-NP
summaries  	summaries  	 NNS	I-NP
and  	and  	 CC	O
death  	death  	 NN	B-NP
certificates  	certificates  	 NNS	I-NP
may  	may  	 MD	O
lack  	lack  	 VB	O
sufficient  	sufficient  	 JJ	O
descriptive  	descriptive  	 JJ	B-NP
information  	information  	 NN	I-NP
needed  	needed  	 VBN	O
to  	to  	 TO	O
confirm  	confirm  	 VB	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
diagnoses 	diagnoses 	 NN	I-NP
.  	.  	 .	O
Clinic  	Clinic  	 NNP	O
staff  	staff  	 NN	O
are  	are  	 VBP	O
unable  	unable  	 JJ	O
to  	to  	 TO	O
provide  	provide  	 VB	O
corroborating  	corroborating  	 JJ	O
documentation  	documentation  	 NN	B-NP
for  	for  	 IN	O
2 	2 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
ALLHAT  	ALLHAT  	 NNP	B-NP
event  	event  	 NN	I-NP
reports 	reports 	 NNS	I-NP
.  	.  	 .	O
Efforts  	Efforts  	 NNS	O
to  	to  	 TO	O
authenticate  	authenticate  	 VB	O
the  	the  	 DT	O
HF  	HF  	 NNP	B-NP
events  	events  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 NN	B-NP
and  	and  	 CC	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
groups  	groups  	 NNS	I-NP
represented  	represented  	 VBD	O
a  	a  	 DT	O
desirable  	desirable  	 JJ	O
step  	step  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
examination  	examination  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
increased  	increased  	 JJ	O
rate  	rate  	 NN	O
of  	of  	 IN	O
HR  	HR  	 NNP	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
group 	group 	 NN	I-NP
.  	.  	 .	O
All  	All  	 DT	O
methods  	methods  	 NNS	O
employed  	employed  	 VBN	O
provided  	provided  	 VBN	O
confirmatory  	confirmatory  	 JJ	B-NP
evidence  	evidence  	 NN	I-NP
that  	that  	 IN	O
both  	both  	 PDT	O
the  	the  	 DT	O
HF  	HF  	 NNP	B-NP
diagnosis  	diagnosis  	 NN	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
difference  	difference  	 NN	O
in  	in  	 IN	O
HF  	HF  	 NNP	B-NP
rates  	rates  	 NNS	I-NP
noted  	noted  	 VBD	O
between  	between  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 NN	B-NP
and  	and  	 CC	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
groups  	groups  	 NNS	I-NP
were  	were  	 VBD	O
valid 	valid 	 JJ	O
.  	.  	 .	O
Results  	Results  	 NNS	O
of  	of  	 IN	O
this  	this  	 DT	O
exploratory  	exploratory  	 JJ	B-NP
investigation  	investigation  	 NN	I-NP
support  	support  	 NN	I-NP
the  	the  	 DT	O
event  	event  	 NN	B-NP
ascertainment  	ascertainment  	 NN	I-NP
methods  	methods  	 NNS	I-NP
developed  	developed  	 VBN	O
for  	for  	 IN	O
ALLHAT 	ALLHAT 	 NNP	B-NP
,  	,  	 ,	O
specifically  	specifically  	 RB	O
for  	for  	 IN	O
HF  	HF  	 NNP	B-NP
events 	events 	 NNS	I-NP
.  	.  	 .	O
This  	This  	 DT	O
validation  	validation  	 JJ	B-NP
exercise  	exercise  	 NN	I-NP
further  	further  	 RB	O
illustrates  	illustrates  	 VBZ	O
the  	the  	 DT	O
ability  	ability  	 NN	B-NP
of  	of  	 IN	O
large 	large 	 JJ	O
,  	,  	 ,	O
simple  	simple  	 JJ	O
trials  	trials  	 NNS	O
to  	to  	 TO	O
answer  	answer  	 VB	O
important  	important  	 JJ	O
public  	public  	 JJ	B-NP
health  	health  	 NN	I-NP
questions  	questions  	 NNS	I-NP
requiring  	requiring  	 VBG	O
large  	large  	 JJ	O
sample  	sample  	 NN	O
sizes  	sizes  	 NNS	O
and  	and  	 CC	O
to  	to  	 TO	O
grapple  	grapple  	 VB	O
with  	with  	 IN	O
unexpected  	unexpected  	 JJ	O
results  	results  	 NNS	O
in  	in  	 IN	O
a  	a  	 DT	O
responsible  	responsible  	 JJ	O
and  	and  	 CC	O
meaningful  	meaningful  	 JJ	O
manner 	manner 	 NN	O
.  	.  	 .	O
Competing  	Competing  	 VBG	B-NP
Interests  	Interests  	 NNP	I-NP
The  	The  	 DT	O
authors  	authors  	 NNS	O
of  	of  	 IN	O
this  	this  	 DT	O
paper  	paper  	 NN	O
disclose  	disclose  	 VB	O
their  	their  	 PRP$	O
affiliations  	affiliations  	 NN	B-NP
with  	with  	 IN	O
Aventis  	Aventis  	 NNP	B-NP
( 	( 	 -LRB-	O
A 	A 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
Abbott  	Abbott  	 NNP	B-NP
( 	( 	 -LRB-	O
AB 	AB 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
AstraZeneca  	AstraZeneca  	 NNP	B-NP
( 	( 	 -LRB-	O
AZ 	AZ 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
Bayer  	Bayer  	 NNP	O
( 	( 	 -LRB-	O
B 	B 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
Biovail  	Biovail  	 NNP	B-NP
( 	( 	 -LRB-	O
BV 	BV 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
Bristol-Myers  	Bristol-Myers  	 NNP	B-NP
Squibb  	Squibb  	 NNP	I-NP
( 	( 	 -LRB-	O
BMS 	BMS 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
Forest  	Forest  	 NNP	O
( 	( 	 -LRB-	O
F 	F 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
Glaxo-SmithKline 	Glaxo-SmithKline 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
SmithKline  	SmithKline  	 NNP	I-NP
Beecham  	Beecham  	 NNP	I-NP
( 	( 	 -LRB-	O
GSK 	GSK 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
SKB 	SKB 	 NNP	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
King  	King  	 NNP	B-NP
Pharmaceuticals 	Pharmaceuticals 	 NNP	I-NP
/ 	/ 	 NNP	I-NP
Monarch  	Monarch  	 NNP	I-NP
( 	( 	 -LRB-	O
KM 	KM 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
Merck  	Merck  	 NNP	O
( 	( 	 -LRB-	O
M 	M 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
Novartis  	Novartis  	 NNP	B-NP
( 	( 	 -LRB-	O
N 	N 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
Nu-Pharm  	Nu-Pharm  	 NNP	B-NP
( 	( 	 -LRB-	O
NP 	NP 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
Pharmacia 	Pharmacia 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
Upjohn  	Upjohn  	 NNP	I-NP
( 	( 	 -LRB-	O
PHU 	PHU 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
Pfizer 	Pfizer 	 NNP	B-NP
,  	,  	 ,	O
Inc.  	Inc.  	 NNP	O
( 	( 	 -LRB-	O
P 	P 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
Sankyo  	Sankyo  	 NNP	B-NP
( 	( 	 -LRB-	O
SY 	SY 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
Searle  	Searle  	 NNP	B-NP
( 	( 	 -LRB-	O
SE 	SE 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
Solvay  	Solvay  	 NNP	B-NP
( 	( 	 -LRB-	O
SV 	SV 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
Takeda  	Takeda  	 NNP	O
( 	( 	 -LRB-	O
T 	T 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
These  	These  	 DT	O
relate  	relate  	 NN	O
to  	to  	 TO	O
personal  	personal  	 JJ	O
or  	or  	 CC	O
institutional-affiliated  	institutional-affiliated  	 JJ	O
receipt  	receipt  	 NN	O
of  	of  	 IN	O
income  	income  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
areas  	areas  	 NNS	O
of  	of  	 IN	O
research  	research  	 NN	B-NP
grants 	grants 	 NNS	I-NP
,  	,  	 ,	O
consultant  	consultant  	 NN	B-NP
fees 	fees 	 NNS	I-NP
,  	,  	 ,	O
or  	or  	 CC	O
other  	other  	 JJ	O
compensation 	compensation 	 NN	B-NP
:  	:  	 :	O
BRD  	BRD  	 NNP	B-NP
( 	( 	 -LRB-	O
AB 	AB 	 NNP	B-NP
, 	, 	 ,	O
BMS 	BMS 	 NNP	B-NP
, 	, 	 ,	O
F 	F 	 NNP	O
, 	, 	 ,	O
M 	M 	 NNP	O
, 	, 	 ,	O
P 	P 	 NN	O
, 	, 	 ,	O
PHU 	PHU 	 NNP	B-NP
, 	, 	 ,	O
GSK 	GSK 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
SKB 	SKB 	 NNP	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
WCC  	WCC  	 NNP	B-NP
( 	( 	 -LRB-	O
AZ 	AZ 	 NNP	B-NP
, 	, 	 ,	O
BMS 	BMS 	 NNP	B-NP
, 	, 	 ,	O
F 	F 	 NNP	O
, 	, 	 ,	O
M 	M 	 NNP	O
, 	, 	 ,	O
P 	P 	 NN	O
, 	, 	 ,	O
PHU 	PHU 	 NNP	B-NP
, 	, 	 ,	O
SY 	SY 	 NNP	B-NP
, 	, 	 ,	O
SE 	SE 	 NNP	B-NP
, 	, 	 ,	O
SV 	SV 	 NNP	B-NP
, 	, 	 ,	O
T 	T 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
JTW  	JTW  	 NNP	B-NP
( 	( 	 -LRB-	O
A 	A 	 NNP	O
, 	, 	 ,	O
B 	B 	 NNP	O
, 	, 	 ,	O
BMS 	BMS 	 NNP	B-NP
, 	, 	 ,	O
F 	F 	 NNP	O
, 	, 	 ,	O
KM 	KM 	 NNP	B-NP
,  	,  	 ,	O
M 	M 	 NNP	O
, 	, 	 ,	O
N 	N 	 NNP	O
, 	, 	 ,	O
P 	P 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
FHHL  	FHHL  	 NNP	B-NP
( 	( 	 -LRB-	O
AZ 	AZ 	 NNP	B-NP
, 	, 	 ,	O
B 	B 	 NNP	O
, 	, 	 ,	O
BMS 	BMS 	 NNP	B-NP
, 	, 	 ,	O
M 	M 	 NNP	O
, 	, 	 ,	O
NP 	NP 	 NNP	B-NP
, 	, 	 ,	O
P 	P 	 NN	O
, 	, 	 ,	O
PHU 	PHU 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
LJH  	LJH  	 NNP	B-NP
( 	( 	 -LRB-	O
PHU 	PHU 	 NNP	B-NP
) 	) 	 -RRB-	O
;  	;  	 :	O
the  	the  	 DT	O
other  	other  	 JJ	O
authors  	authors  	 NNS	O
report  	report  	 VBP	O
no  	no  	 RB	O
competing  	competing  	 VBG	B-NP
interests 	interests 	 NNS	I-NP
.  	.  	 .	O
Additional  	Additional  	 JJ	B-NP
Information  	Information  	 NNP	I-NP
1 	1 	 CD	O
)  	)  	 -RRB-	O
New  	New  	 NNP	B-NP
York  	York  	 NNP	I-NP
Heart  	Heart  	 NNP	I-NP
Classification  	Classification  	 NNP	I-NP
functional  	functional  	 JJ	I-NP
class  	class  	 NN	I-NP
III 	III 	 NNP	I-NP
:  	:  	 :	O
"Patients  	"Patients  	 CD	O
with  	with  	 IN	O
cardiac  	cardiac  	 JJ	B-NP
disease  	disease  	 NN	I-NP
resulting  	resulting  	 VBG	O
in  	in  	 IN	O
marked  	marked  	 JJ	O
limitation  	limitation  	 NN	O
of  	of  	 IN	O
physical  	physical  	 JJ	B-NP
activity 	activity 	 NN	I-NP
.  	.  	 .	O
They  	They  	 PRP	O
are  	are  	 VBP	O
comfortable  	comfortable  	 JJ	O
at  	at  	 IN	O
rest 	rest 	 NN	O
.  	.  	 .	O
Less  	Less  	 RBR	O
than  	than  	 IN	O
ordinary  	ordinary  	 JJ	B-NP
physical  	physical  	 JJ	I-NP
activity  	activity  	 NN	I-NP
causes  	causes  	 VBZ	O
fatigue 	fatigue 	 VBN	O
,  	,  	 ,	O
palpitation 	palpitation 	 NN	O
,  	,  	 ,	O
dyspnea 	dyspnea 	 NN	B-NP
,  	,  	 ,	O
or  	or  	 CC	O
anginal  	anginal  	 JJ	B-NP
pain. 	pain. 	 NN	I-NP
"  	"  	 ''	O
1994  	1994  	 CD	O
Revisions  	Revisions  	 NNS	O
to  	to  	 TO	O
Classification  	Classification  	 NNP	B-NP
of  	of  	 IN	I-NP
Functional  	Functional  	 NNP	I-NP
Capacity  	Capacity  	 NNP	I-NP
and  	and  	 CC	O
Objective  	Objective  	 NNP	B-NP
Assessment  	Assessment  	 NNP	I-NP
of  	of  	 IN	O
Patients  	Patients  	 NNS	O
with  	with  	 IN	O
Diseases  	Diseases  	 NNP	O
of  	of  	 IN	O
the  	the  	 DT	O
Heart 	Heart 	 NNP	O
:  	:  	 :	O
AHA  	AHA  	 NNP	B-NP
Medical 	Medical 	 NNP	I-NP
/ 	/ 	 NNP	I-NP
Scientific  	Scientific  	 NNP	I-NP
Statement.  	Statement.  	 CD	I-NP
2 	2 	 CD	O
)  	)  	 -RRB-	O
The  	The  	 DT	O
ALLHAT  	ALLHAT  	 NNP	B-NP
Manual  	Manual  	 NNP	I-NP
of  	of  	 IN	O
Operations  	Operations  	 NNP	O
provides  	provides  	 VBZ	O
for  	for  	 IN	O
prescription  	prescription  	 NN	B-NP
of  	of  	 IN	I-NP
open-label  	open-label  	 JJ	I-NP
medicines  	medicines  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
same  	same  	 JJ	O
class  	class  	 NN	O
as  	as  	 IN	O
the  	the  	 DT	O
blinded  	blinded  	 JJ	O
medications 	medications 	 NN	O
,  	,  	 ,	O
when  	when  	 WRB	O
a  	a  	 DT	O
compelling  	compelling  	 JJ	O
indication  	indication  	 NN	O
exists 	exists 	 VBZ	O
,  	,  	 ,	O
such  	such  	 JJ	O
that  	that  	 IN	O
the  	the  	 DT	O
total  	total  	 JJ	B-NP
dose  	dose  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
added  	added  	 JJ	O
open-label  	open-label  	 JJ	B-NP
drug  	drug  	 NN	I-NP
should  	should  	 MD	O
not  	not  	 RB	O
exceed  	exceed  	 VB	O
1 	1 	 CD	O
/ 	/ 	 CD	O
2  	2  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
maximum  	maximum  	 JJ	B-NP
dose  	dose  	 NN	I-NP
as  	as  	 IN	O
recommended  	recommended  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
Sixth  	Sixth  	 NNP	B-NP
Report  	Report  	 NNP	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
Joint  	Joint  	 NNP	O
National  	National  	 NNP	B-NP
Committee  	Committee  	 NNP	I-NP
on  	on  	 IN	O
Detection 	Detection 	 NNP	O
,  	,  	 ,	O
Evaluation  	Evaluation  	 NNP	O
and  	and  	 CC	O
Treatment  	Treatment  	 NNP	O
of  	of  	 IN	O
High  	High  	 NNP	O
Blood  	Blood  	 NNP	O
Pressure  	Pressure  	 NNP	O
( 	( 	 -LRB-	O
JNC  	JNC  	 NNP	B-NP
VI 	VI 	 NNP	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
If  	If  	 IN	O
a  	a  	 DT	O
compelling  	compelling  	 JJ	O
reason  	reason  	 NN	O
requires  	requires  	 VBZ	O
a  	a  	 DT	O
higher  	higher  	 JJR	O
dose 	dose 	 NN	O
,  	,  	 ,	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
permitted.  	permitted.  	 CD	O
3 	3 	 CD	O
)  	)  	 -RRB-	O
The  	The  	 DT	O
ALLHAT  	ALLHAT  	 NNP	B-NP
follow-up  	follow-up  	 JJ	I-NP
form  	form  	 NN	I-NP
allows  	allows  	 VBZ	O
for  	for  	 IN	O
reporting  	reporting  	 VBG	O
of  	of  	 IN	O
open-label  	open-label  	 JJ	B-NP
ACE-inhibitors  	ACE-inhibitors  	 JJ	I-NP
and  	and  	 CC	O
diuretics 	diuretics 	 NNS	B-NP
;  	;  	 :	O
among  	among  	 IN	O
beta-blockers 	beta-blockers 	 NNP	B-NP
,  	,  	 ,	O
only  	only  	 JJ	O
atenolol  	atenolol  	 NN	B-NP
is  	is  	 VBZ	O
reported 	reported 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
other  	other  	 JJ	O
beta-blockers  	beta-blockers  	 JJ	B-NP
cannot  	cannot  	 NNS	O
be  	be  	 VB	O
ascertained  	ascertained  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
data 	data 	 NNS	O
.  	.  	 .	O
